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ABSTRACT

BIOCHEMISTRY OF HUNK KINASE: ACTIVATION BY LKB1 AND
IDENTIFICATION OF FIRST SUBSTRATES
Samuel E. Getchell
Lewis A. Chodosh
Protein phosphorylation is the most common form of reversible post-translational
modification1. Phosphorylation is controlled by at least 518 different kinases and at least
156 different phosphatases, meaning that over 2% of the human genome is dedicated to
managing phosphorylation2,3. The two major protein kinase types are specific for either
serine/threonine residues or tyrosine residues, though there are a number of dual
specificity kinases that can phosphorylate serine, threonine, and tyrosine residues4.
Signal transduction networks using phosphorylation regulate nearly every aspect of
cellular function, and alterations to the activity of kinases and phosphatases underlies
many human diseases, with cancer being a prominent example5.
HUNK (Hormonally Up-regulated Neu-associated Kinase) is a protein kinase
associated with aggressive subsets of human cancer and required for efficient
tumorigenesis, metastasis, and tumor cell survival in several genetically engineered
mouse models of cancer6–8. HUNK is a member of the AMPK (5' Adenosine
Monophosphate-activated Protein Kinase) subfamily of serine/threonine directed kinases,
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collectively known as the AMPK Related Kinases (ARKs). Fourteen out of seventeen of
the ARKs are phosphorylated and activated by LKB1 (Liver Kinase B1), also known as
Serine/Threonine Kinase 11 (STK11)9,10. We provide evidence below that LKB1
regulates HUNK in the same manner, phosphorylating a conserved threonine residue in
the T-Loop of HUNK and increasing its activity as measured both by
autophosphorylation and by substrate phosphorylation. This suggests that HUNK is
potential effector for LKB1 dependent phenotypes.
We also sought to elucidate mechanisms of HUNK-dependent signal transduction
by identifying substrates of HUNK kinase using a kinase assay on protein microarrays.
We generated a ranked list of candidate substrates, and confirmed that both CHK2 and
CAMKKβ are phosphorylated by HUNK. We further provide preliminary data consistent
with role for HUNK in the activation of the ATM/CHK2 pathway in response to DNA
damage. These data support the view of HUNK as a valuable therapeutic target in human
cancer.
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CHAPTER 1: INTRODUCTION
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Published work from our lab indicates that HUNK is a viable therapeutic target in
several human cancers wherein it serves to promote tumorigenesis, metastasis, and tumor
cell survival. To better understand the molecular interactions regulating these
phenotypes, we conducted experiments to show that LKB1 phosphorylates and activates
HUNK, indicating HUNK is a potential effector for LKB1 dependent pathways. We
therefore begin with a brief review of HUNK, LKB1, and the LKB1 regulated kinases
collectively known as the ARKs.

HUNK kinase.
HUNK is a member of the SNF1 family of serine/threonine kinases, also known
as the AMPK-Related Kinases, and was initially identified in a mammary epithelial cell
line derived from a tumor that arose in an MMTV-neu transgenic mouse 11. Subsequent
work in mice revealed that HUNK is located on distal mouse chromosome 16, is
transcribed into 5.1 and 5.6 kb mRNA species, and encodes an 80-kDa protein of 714
amino acids12. HUNK expression is both temporally regulated during murine
development and spatially regulated within a variety of tissues, suggesting multiple
potential roles in the developing and adult organism12.
HUNK appears to play a role in hormone induced changes in the mammary gland
as its expression is induced by the steroid hormones 17β-estradiol and progesterone with
peak expression at day 7 of pregnancy, expression nearly absent during lactation, and
higher again during involution13. Consistent with the hypothesis that HUNK controls
mammary gland development during pregnancy, mice engineered to overexpress HUNK
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in the mammary epithelium show defects in both differentiation and proliferation of these
tissues13.
Multiple lines of evidence implicate HUNK in promoting the development and
progression of cancers in a variety of contexts. For example, HUNK expression is
significantly higher in aggressive subsets of human cancers, including lymph node
positive breast cancers, HER2-amplified breast cancers, and poorly differentiated cancers
of the breast, ovary, and colon6. Consistent with a functional role for HUNK in
tumorigenesis, HUNK is required for primary mammary tumor formation in mouse
models of breast cancer driven by HER2/neu overexpression or PTEN deletion7,8, and
HUNK expression and kinase activity are required for the metastasis of mammary tumors
driven by c-MYC6.
While the precise molecular mechanisms controlling HUNK-dependent
phenotypes are unknown, several mechanistic details are known. HUNK suppresses
apoptosis in mouse models of cancer driven by HER2/neu overexpression or PTEN
deletion7,8, in the former by negative regulation of p27kip1 expression and nuclear
localization and in the latter by negative regulation of c-Myc expression. HUNK
expression is required in HER2-positive human cancer cell lines for full activation of
autophagy and JNK kinase signaling14,15. Inhibition of HER2/neu or PI3K/Akt activity
down-regulates HUNK expression7. Work performed in the Korobko lab suggests that
the kinase domain and the UBA are required to localize a portion of cellular HUNK to
the plasma membrane in a variety of cell lines and in yeast16.
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While several mechanistic details of HUNK-dependent pheontypes are known,
the work described herein is the first to characterize immediate molecular interactions, in
particular activation of HUNK by LKB1 and identification of substrates of HUNK.
HUNK is a member of the AMPK (5' Adenosine Monophosphate-activated Protein
Kinase) subfamily of kinases, and as members of this subfamily are activated by LKB1
phosphorylation of a conserved threonine residue in their T-Loops, we investigated
whether HUNK was also regulated in this manner.
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Figure 1. Model of LKB1 activation of and binding to HUNK. Arrows indicate
phosphorylation, green indicates activation. Dotted line indicates binding. (A) The
LKB1 heterotrimer, consisting of LKB1, MO25, and STRAD, phosphorylates HUNK on
multiple sites, with phosphorylation at T222 of HUNK resulting in increased HUNK
kinase activity. HUNK then autophosphorylates at a number of sites and phosphorylates
substrates. (B) HUNK binds to complexes of LKB1 that contain STRADβ but not
STRADα. STRADβ containing complexes localize primarily to the nucleus, while
STRADα complexes are primarily cytoplasmic, and HUNK localizes to both the nucleus
and the cytoplasm.
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LKB1 and Peutz-Jeghers syndrome.
LKB1 was first identified in 1998 as the gene whose germline mutation and
inactivation results in Peutz-Jeghers syndrome (PJS)17,18. The first report of a patient
bearing one of the syndrome’s most obvious symptoms was probably made in 1896 by
the British surgeon Jonathan Hutchinson, who reported identical twins with spots on and
around the lips and mouth19. The connection between polyps and spots was made in
1921 in a published case report by the Dutch internist Johannes Laurentius Augustinus
Peutz20. PJS was formally recognized as a syndrome with autosomal dominant
inheritance in 1949 by the American internist Harold Joseph Jeghers21. The National
Institutes of Health (NIH) estimates the frequency of PJS as 1 in 25,000 to 300,00022.
PJS patients manifest a range of symptoms. The earliest presenting symptom can
be dark freckles on and around the lips of a newborn. Patients often present by age five
with mucocutaneous pigmentation (small dark spots). Other symptoms include clubbed
fingers or toes, abdominal cramping, intestinal hamartomatous polyps, and intestinal
intussusception (part of the intestine folded in on itself). Repeated surgical intervention
can be required to resolve intestinal blockage due to polyps or intussusception23,24.
Perhaps the most clinically significant manifestation of PJS is an increased risk of
a range of cancers. A meta-analysis performed in 2010 found the lifetime relative risk of
any type of cancer to be as much as 18 times higher than the general population25, with an
increased risk of malignancies including small intestinal, gastric, pancreatic, colorectal,
ovarian, lung, endometrial, and breast (see Table 1)17,18.
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Table 1. Cumulative cancer risks (approaching lifetime risks)
Site
Age (years) Cumulative Risk
Any cancer
60-70
37-93%
Gastrointestinal cancer 60-70
38-66%
Gynecological cancer
60-70
13-18%
Per origin
Stomach
65
29%
Small bowel
65
13%
Colorectum
65
39%
Pancreas
65-70
11-36%
Lung
65-70
7-17%
Breast
65-70
32-54%
Uterus
65
9%
Ovary
65
21%
Cervix
65
10%
Testes
65
9%
Adapted from van Lier et al., 2010, Am J Gastroenterol.

In 1997, Hemminki et al. discovered a genetic susceptibility locus for PJS at
chromosome 19p26. In 1998, Hemminki et al. and Jenne et al. independently reported
that LKB1 is the gene mutated in PJS17,18. Germline mutation of LKB1 is found in 6694% of PJS patients27–29, and no mutations in LKB1-interacting proteins were found in
two genetic screens of PJS patients30,31, suggesting that loss of LKB1 function accounts
for nearly if not all cases of PJS.

LKB1 and tumor suppression.
Evidence for the tumor suppressive role of LKB1 extends beyond the increased
risk of cancer is in PJS patients. Consistent with LKB1’s identification as a bona fide
tumor suppressor, somatic mutation or deletion of LKB1 (STK11) occurs in 15-20% of
lung adenocarcinomas and in 1-10% of cancers of the ovary, bladder, cervix, pancreas,
esophagus, stomach, thyroid, colon and breast32–39. Examination of data from The
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Cancer Genome Atlas (TCGA) reveals that LKB1 is the third most commonly mutated
gene in human lung adenocarcinoma (ADC)33.
In 1999, LKB1 expression was reintroduced in several LKB1-deficient tumor cell
lines, which induced a G1 cell cycle arrest without altering apoptosis40,41. In at least one
cell line (SW13 adrenal carcinoma cell line), LKB1 physically associated with BRG1 and
LKB1 expression, but not kinase activity, was demonstrated to be necessary for BRG1induced growth arrest42.

Regulation of LKB1.
LKB1 expression is at least partially controlled by the miR-17∼92 microRNA
cluster, which is itself a direct transcriptional target of Myc43,44. Suppression of LKB1 by
miR-17 relieves mTORC1 inhibition by AMPK, promoting metabolic reprogramming
and lymphomagenesis in animal models45. Consistent with this, miR-17~92 expression is
elevated in cancers of the colon45, lung46, and DLBCL47.
LKB1 activity is controlled primarily by complex formation, as it is inactive
unless in a complex with the scaffold protein MO25 (mouse protein 25) and the
pseudokinase STRAD (STE20-Related Kinase Adaptor)48,49. LKB1 does not require
phosphorylation of its T-Loop in order to be activated by binding to MO25/STRAD50.
MO25 and STRAD each have two principal isoforms, alpha and beta. These MO25
isoforms are 80% conserved at the amino acid level, while STRAD isoforms are only
42% conserved and STRADα has two nuclear export sequences (NES) that are lacking in
STRADβ (Figure 2).
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While MO25 isoforms serve the same function, the alpha isoform has a slightly
greater ability to activate LKB1, which is attributable to stabilization of the ternary
complex by MO2550. The differences between the STRAD isoforms have been largely
neglected in the literature, despite evidence in 2008 showing that STRADα, but not
STRADβ, can effectively localize active LKB1 to the cytoplasm where it can activate
AMPK51. Kinase-deficient mutants of LKB1 localize predominantly to the nucleus40.
LKB1 is shuttled into the nucleus by direct interaction with importins-α/β, and LKB1 is
exported from the nucleus through its interaction with STRADα, which binds CRM7 and
Exp751. STRADα also inhibits binding of LKB1 to importins. For STRAD, as with
MO25, the alpha isoform has a greater ability to activate LKB110,49.
Veleva-Rotse et al. demonstrated in 2014 that while either STRADα or STRADβ
are sufficient to drive axon formation in the developing cortex, STRADα but not
STRADβ is required in vivo for mutual stabilization of protein levels with LKB152. This
same group also established that the splice variant isoforms of STRADα are tissue
specific and developmentally regulated, indicating a need for further study of the impact
of STRAD isoforms on LKB1 signal transduction.
Several post translational modifications (PTM) influence the localization of
LKB1. LKB1 can be deacetylated by SIRT1 and this correlates with an increase in
activity and cytoplasmic localization in HEK293T cells, with the most important site for
deacetylation being K48 in LKB153. SIRT1 has also been shown to control LKB1
activation in the HepG2 hepatocyte cell line54. In an elegant murine system with whole
body inducible knockout of SIRT1, SIRT1 is required for increased AMPK activation,
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mitochondrial biogenesis and function, and increased NAD+ levels in skeletal muscle in
mice treated with moderate doses of resveratrol55.
LKB1 is regulated by modification with both ubiquitin and SUMO. Skp2
ubiquitination of LKB1 is required for robust formation of the LKB1 heterotrimer and
oncogenic Ras-G12V activity markedly increases LKB1 activity in cells56. Consistent
with this, both Skp2 and LKB1 are overexpressed in hepatocelluar carcinoma (HCC) and
high expression is predictive of reduced overall survival56. Sumoylation of LKB1 at
L178 is triggered by energy stress and is essential for promoting interaction with and
activation of AMPK via a SUMO-interacting motif (SIM) in AMPK57.
LKB1 has three isoforms, with the full length being the most abundantly
expressed. There is also a splice variant altered in the C-terminus that is expressed in
sperm and required for spermiogenesis58. The third isoform of LKB1 is catalytically
inactive due to omission of a large portion of the N-terminus, but it potentiates AMPK
activation by binding to the autoinhibitory domain (AID) of AMPK and, in some
contexts, is oncogenic59.
The orphan nuclear receptor Nur77 binds LKB1 in the nucleus, modestly
decreasing its cytoplasmic/nuclear partitioning ratio and thereby reducing AMPK
activation60.
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Figure 2. Amino acid conservation in LKB1 complex members MO25 and STRAD.
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AMPK (5' Adenosine Monophosphate-activated Protein Kinase).
Much of the growth suppression induced by LKB1 is mediated through its most
studied substrate, AMPK. Three independent groups reported in late 2003 and early
2004 that LKB1 is the upstream activating kinase for AMPK49,61,62.
AMPK is a key enzyme in the maintenance of cellular energy homeostasis.
AMPK senses the lowering of cellular energy levels via the relative levels of ATP, ADP,
and AMP (adenosine tri-, di-, and mono-phosphate). When the cellular AMP:ATP ratio
rises, AMPK is activated and phosphorylates a number of substrates to shift cellular
activity from energy consuming to energy producing pathways63,64. AMPK also regulates
energy homeostasis at the level of the whole organism by influencing appetite and
circadian rhythm64,65.
AMPK inhibits lipid anabolism and promotes lipid catabolism, and promotes
glucose uptake and glycolysis while inhibiting glycogen synthesis and gluconeogenesis66.
AMPK inhibits protein synthesis through multiple mechanisms, including indirectly
inhibiting mTORC1 by phosphorylating both TSC2 and raptor67. AMPK can promote
autophagy via direct and indirect mechanisms, which both provides additional energy to
the cell and promotes the turnover of damaged mitochondria68. AMPK promotes the
cellular defense against reactive oxygen species (ROS) through both short and long term
mechanisms69.
According to the theory of the stress hallmarks of cancer, tumor cells undergo
DNA damage and replication stress, proteotoxic stress, mitotic stress, metabolic stress,
and oxidative stress70. Early in tumorigenesis, when cells are exposed to increasing
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levels of these stresses, AMPK is activated and limits growth of the tumor cells both by
mechanisms mentioned above and by activation of p53 via Ser-15 phosphorylation,
which then activates the CDKI p21CIP, leading to reversible arrest at the G1/S boundary71.
Sustained activation of this checkpoint can lead to cellular senescence.
More advanced tumors can evade checkpoint-induced arrest, continuing to
proliferate under stress conditions72. In these circumstances, AMPK can promote tumor
cell survival by a variety of mechanisms. AMPK activity promotes lung tumor cell
survival during metabolic stress by maintaining NADPH homeostasis, allowing cells to
buffer ROS69. AMPK is active in human patient prostate cancer (PC) samples and is
required for survival and proliferation of PC cell lines73. AMPK inhibits cisplatininduced apoptosis in multiple tumor cell lines via both inhibition of mTORC1 and
induction of autophagy74.
AMPK functions as a heterotrimeric complex of one catalytic α subunit and one
each of the regulatory β and γ subunits, and humans have two paralogs for α and β and
three isoforms for γ75. This gives twelve possible subunit configurations, and evidence
exists suggesting that the different complexes have different function and regulation76.
After complex formation, AMPK activity is regulated by both allostery and
phosphorylation of T172 in the α catalytic subunit. ATP, ADP, and AMP bind
competitively to the γ subunit, with AMP and, to a lesser extent, ADP allosterically
protecting T172 of the catalytic α from dephosphorylation, thereby promoting its
phosphorylation and activating AMPK ~10-fold 77.
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AMPK activity increases at least 100-fold upon phosphorylation of AMPKα at the
T-Loop residue T17278. While LKB1 is the major upstream activating kinase,
phosphorylation of AMPKα at T172 is regulated by at least three kinases and three
phosphatases: LKB1, Ca2+/calmodulin-dependent protein kinase kinase-beta
(CAMKKβ), TGFβ-activated kinase 1 (TAK1); protein phosphatase 2A (PP2A); protein
phosphatase 2C (PP2C) and Mg2+-/Mn2+-dependent protein phosphatase 1E
(PPM1E)77,79–84.

LKB1 and the ARKs.
Beyond its regulation of AMPK, LKB1 regulates cellular metabolism, polarity,
and proliferation by activating a group of kinases collectively referred to as the AMPKrelated kinases (ARKs). These kinases share a common domain structure with an Nterminal kinase domain, followed by a UBA (ubiquitin-associated) domain in all save the
AMPKs and NUAKs. The MARKs possess a KA1 (Kinase Associated 1) domain that
binds acidic phospholipids. AMPKs are the only ARKs activated by stimuli such as
AICAR, phenformin, or increased cellular AMP9. All ARKs are activated
phosphorylation of a conserved threonine on their T-Loop. NIM1 and MELK can
autophosphorylate, whereas LKB1 activates the other 15 family members. MARK1-3
also are phosphorylated by LKB1 on a serine 4 residues C-terminal to the conserved
threonine. AMPK is also activated by two other kinases that phosphorylate the conserved
threonine, TAK1 (TGFβ-activated kinase 1) and CAMKKβ79,81,82.
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The UBAs of the ARKs fold into three-helix bundles that weakly interact with
ubiquitin or polyubiquitin chains85. There is sequence homology between the UBAs of
the ARKs and the AID (autoinhibitory domain) of AMPK86. Mutation of a key residue in
the UBA has been shown to abrogate activation by LKB186. Crystal structures and
kinase assays of MARK1 and MARK2 show that the UBA can bind directly to the
catalytic domain and inhibit kinase activity86, though NMR studies show that the
MARK3 UBA is highly dynamic and exists in a rapid unfolding/refolding equilibrium87.
The ARKs are polyubiquitinated by unusual Lys-29 and Lys-33-linked chains,
and MARK4 and NUAK2 are clients of the deubiquitinase USP9X, which removes
polyubiquitin and allows activation by LKB188. The 14-3-3 family of scaffolding
proteins also bind to at least the MARK and SIK kinases, anchoring them in the
cytoplasm without otherwise affecting kinase activity89–91.

BRSK/SAD Kinase (Brain-Specific Serine/Threonine-Protein Kinase, Synapses of
Amphids Defective Homolog).
SAD kinases have expression in a range of tissues with highest levels in the
brain92. There are two main paralogs of the protein, BRSK1/SAD-A and BRSK2/SADB. One of the best studied functions of BRSK is the regulation of polarization of
neurons93. SAD-A/B kinases regulate multiple steps in neuronal development and
differentiation, including axon specifications and maturation in both the central and
peripheral nervous system94. Consistent with this, SAD-B dependent regulation of
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vesicular trafficking and vesicular release probability at pre-synaptic terminals in the
hippocampus is required for contextual fear learning in mice94.
SAD kinases also have important functions in the regulation of cell division and
DNA damage. SAD-B phosphorylation of γ-tubulin at Ser-131 regulates centrosome
duplication via control of CP110 affinity for nascent centrioles, where CP110 forms a
cap, terminating growth of the centriole and seeding growth of centriolar microtubules95.
Phosphomimetic mutation of γ-tubulin (S131D) increased centrosome numbers and
phospho-ablative (S131A) mutation impaired centrosome duplication95. SAD-B localizes
to chromatin and centrosomes and promotes the nuclear localization of γ-tubulin by
phosphorylation of Ser-385 in a manner enhanced by the SAD-B phosphorylation of γtubulin at Ser-13196. While the link between impaired centrosome duplication and cancer
is established97, the link between SAD kinase control of centrosome duplication and
cancer risk in PJS patients is largely unexplored.
DNA damage induced by UV, but not γ-IR, increases kinase activity of SAD-A
and induces it to translocate to the nucleus in A172 cells92. Overexpression of SAD-A in
HeLa cells causes arrest at G2/M, and knockdown of SAD-A by siRNA reduces UVinduced G2/M arrest92.
Regulation of SAD kinases is incompletely understood. LKB1 activation of SAD
kinases has been demonstrated both in vitro and in vivo. While CAMKKα has been
shown to activate SAD-A in vitro and when overexpressed in cells98, there is also
evidence that BRSK activity in the distal region of axons in polarized hippocampal
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neurons does not respond to Ca2+, indicating at least one setting in which CAMKK may
not activate BRSK in vivo99.
Expression of SAD kinases is promoted by mTORC1100. The SAD/BRSK kinases
have a mode of autoinhibition thought to be unique to the ARKs in which an
autoinhibitory sequence (AIS) binds to the junction between the kinase domain and the
UBA (ubiquitin-associated domain), stabilizing an inactive conformation of the kinase101.
The AIS and the KA1 (kinase associated-1) domain cooperate to bind to phospholipids,
resulting in at least partial activation of kinase activity101.

MARK/Par-1 kinases (Microtubule Affinity Regulating Kinase 1/Partitiondefective-1c, MARK2/Par-1b, MARK3/Par-1a/C-TAK1/p78, MARK4/Par-1d).
MARK1/PAR-1 was initially identified in a screen to identify regulators of early
embryonic polarity in Caenorhabditis elegans102. This screen also identified the C.
elegans homolog to LKB1 as PAR-4. Subsequent studies showed that Par-1 is one of
several proteins conserved from yeast to humans required for cellular polarity, including
Par-3/ASIP, Par-4/LKB1, Par-5/14-3-3, Par-6, and aPKC/PKC-3103–113.
Drewes et al. showed in 1997 that MARK1 and MARK2 phosphorylate
microtubule associated proteins (MAPs) MAP2, MAP4, and Tau, at the KXGS motif114.
Tau functions to stabilize microtubules115 and MARK phosphorylation of Tau reduces its
affinity for microtubules, destabilizing them114. Ectopic expression of MARKs in CHO
cells is sufficient to destabilize the microtubule cytoskeleton114. Tau is
hyperphosphorylated at the KXGS motifs in Alzheimer’s disease, leading to formation of
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multiple toxic species of Tao aggregates, with Tau phosphorylated by at least Akt, GSK3β, and MARK2116.
MARK3/p78/C-TAK1 was first implicated in control of cell proliferation when its
loss was associated with transformation of pancreatic cells by treatment with known
carcinogens117. Entry into mitosis is triggered by activity of CDC2/cyclin B complex,
which is activated by CDC25C118. MARK3 prevents mistimed CDC25C activity by
phosphorylating Ser-216 during interphase, promoting binding to 14-3-3 and
sequestration in the cytoplasm of CDC25C118,119. Ser-216 of CDC25C is also
phosphorylated by CHK1 and CHK2 in response to DNA damage, preventing the
crossing of the G2/M checkpoint120.
MARK kinases also control cell proliferation through modulation of Ras
signaling. MARK3 regulates Ras signaling by phosphorylating the motif for 14-3-3
binding to KSR1, preventing improper pathway activation by sequestering MEK from
Raf121,122. KSR1 has also been implicated as a tumor suppressor in breast cancer via
patient expression data and overexpression experiments in mice, where KSR1 was found
to stabilize BRCA1 protein levels123.
In a paper with implications for PJS patients and cancer susceptibility, Mohseni et
al. showed that LKB1-MARK signaling antagonizes YAP nuclear localization as
demonstrated by increased nuclear YAP in LS174T-W4 cells with siRNA against
MARK4124. Furthermore, they also proved that YAP activity is enhanced in several
LKB1-deficient tumor types and in PJS patient polyps, breast adenocarcinoma, and liver
adenocarcinoma. YAP activity is sufficient to overcome LKB1-driven tumor

P a g e | 19
suppression, and YAP is required for efficient growth of LKB1-mutant tumors and
tissues. These data in total suggest that YAP dependence is a promising therapeutic
target in LKB1-deficient tumors.
The MARK kinases possess a KA1 domain (Kinase Associated-1) that serves to
bind acidic phospholipids, particularly phosphatidylserine, thereby promoting membrane
localization and relief of autoinhibition due to interaction between the C-terminal KA1
domain and the kinase domain125. The KA1 domain is not found in other ARKs. MARK
localization is also controlled by binding to 14-3-3 via multiple phosphosites, at least
some of which are generated via autophosphorylation, anchoring MARKs in the
cytosol91.

Salt-Inducible Kinases (SIK1, SIK2/QIK, SIK3/QSK).
One of the primary functions of SIKs is coupling the activity of the Na,K-ATPase
(NK) with intracellular sodium concentration, allowing small increases in sodium to lead
to corrective increases in NK activity, via SIK2 phosphorylation of PME-1, which
associates with the NK α-subunit126. SIK1 also regulates NK, controlling nuclear
localization of cAMP-regulated transcriptional coactivators (CRTCs) to alter
transcription of a number of genes including the β subunit of NK127.
SIKs also signal through CRTCs to regulate metabolism at the level of the whole
organism, constraining expression of genes required for gluconeogenesis and lipogenesis
until SIKs are inactivated by PKA128. Patel et al. took advantage of a highly specific panSIK inhibitor to determine that the SIKs serve to inhibit gluconeogenesis in the liver, and
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SIK2 phosphorylation in the liver is regulated by glucagon and not by insulin, significant
because those hormones serve as the yin and yang (counter-regulatory hormones) to
coordinate hepatic gluconeogenesis and peripheral glucose uptake129,130.
SIK1 is required for p53-dependent anoikis and suppression of metastasis in
immortalized human mammary epithelial cells (tHMEC) and low SIK1 expression levels
predicts increased distal metastasis in human breast cancer131. Consistent with this, SIK1
inhibits migration of the gastrin responsive AGS-GR cell line132.
In addition to regulation by LKB1, SIKs are regulated by 14-3-3, which binds the
phosphorylated form of the T-Loop of SIK1 and SIK3, enhancing cytoplasmic
localization and increasing their kinase activity, likely through increased interaction with
substrate90. SIK1 expression in multiple adenocarcinoma cell lines is induced by the
hormone gastrin and inhibited by ICER (inducible cAMP early repressor)132.

LKB1 and non-ARK Substrates
Evidence has been published that LKB1 phosphorylates at least three substrates
that are not ARKs (Table 2). Song et al. presented data showing that in cultured human
umbilical vein endothelial cells, PKCζ phosphorylates LKB1 at Ser-428, inducing
cytoplasmic localization of LKB1, which leads to phosphorylation of PTEN at Ser-380,
Thr-382, and Thr-383, with in vitro evidence that LKB1 may directly phosphorylate
PTEN133. These phosphorylations activate PTEN, leading to inhibition of Akt.
LKB1 inhibits PAK1 (p21-activated kinase) by phosphorylating Thr-109, which
results in reduced binding to p21134. It is worth noting that of the three putative non-
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ARK substrates of LKB1, this site is the only site with at least partial conservation with
ARK sites, as PAK1 is partially conservative from -3 to +1 with the ARK sites
phosphorylated by LKB1 (Table 2, Figure 2).
Zeng et al. reported convincing data that LKB1 is recruited to the p21/WAF1
promoter by p53 and recruitment of kinase active LKB1 is required for p53-dependent
gene transcription135. They also showed evidence that LKB1 can phosphorylate p53 at
Ser-15 and Ser-392 in vitro, though whether phosphorylation of these sites is determined
by direct action of LKB1 in vivo is less clear.

MW
(DA)

Protein

Gene

Organism

p53

TP53

human

43,653

PAK1

PAK1

human

60,647

PTEN

PTEN

human

47,166

LKB1 Consensus Site

Site

Site_+/-7_AA

S15

PSVEPPLSQETFSDL

S392

FKTEGPDSD______

T109

QWARLLQTSNITKSE

S380

EPDHYRYSDTTDSDP

T382

DHYRYSDTTDSDPEN

T383

HYRYSDTTDSDPENE
xxgxklxTfCGSpxY

Table 2. LKB1 non-ARK Substrates

DNA damage repair
Recent work has uncovered links between LKB1 and the DNA damage response
(DDR), revealing several contexts in which LKB1 is required for a robust cellular
response to DNA damage.
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Wang et al. showed that LKB1 is required for efficient HR-mediated
reconstitution of a GFP reporter gene136. Consistent with this finding, they also
demonstrated that LKB1 deficiency delays repair (but not formation) of γIR-induced
DNA damage as measured by γ-H2AX foci in multiple cancer cell lines. Lastly, they
showed that LKB1 deficiency increases cancer cell sensitivity to both cisplatin and PARP
inhibitors. While the mechanism of LKB1 regulation of DNA damage was largely
uninvestigated in this work, they did show that LKB1 and ATM co-immunoprecipitate
and colocalize with γ-H2AX foci in γ-IR treated cells. ATM associates with LKB1, p53,
and BRCA1 in response to DNA damage and point mutations in ATM between amino
acids 91 and 97 ablate formation of these complexes, providing further evidence for a
role for LKB1 in regulation of HR137. Additional evidence for LKB1 regulation of the
DDR comes from Gupta et al., who in 2015 determined that LKB1 reduces mutation rate
and increases survival after DNA damage by stimulating BRCA1 expression in an at least
partially AMPK-dependent manner138.
Bungard et al. found evidence that AMPKα2 binds and phosphorylates histone
H2B at S36 in response to cellular stress to increase transcription of known AMPKdependent stress response genes139. In 2014, Ui et al. demonstrated that LKB1 controls
BRM-dependent non-homologous end joining, and cells deficient for LKB1 exhibit
marked increases in chromosomal aberrations140. Notably, Ui et al. found that in cells
deficient for AMPKα2, chromosomal aberrations increased only slightly, as opposed to
the large increases in aberrations observed in cells deficient for LKB1. There are at least
two potential reasons for AMPKα2 deficiency failing to account for the full LKB1-
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dependent phenotype: compensation by AMPKα1 and the action of other effectors of
LKB1.
Esteve-Puig et al. have shown that LKB1 haploinsufficient mice exhibit
dramatically increased sensitivity to UVB-induced skin cancer, and both these mice and
LKB1-deficient human keratinocytes exhibit impaired repair of UVB-induced DNA
damage141. LKB1 dependent response to UV-induced DNA damage is at least partially
dependent upon SAD1 kinase, as overexpression of SAD1 in HeLa cells causes arrest at
G2/M, and knockdown of SAD1 by siRNA reduces UV-induced G2/M arrest 92. DNA
damage induced by UV but not γ-IR increases kinase activity of SAD1 and causes it to
translocate to the nucleus in A172 cells92.
In addition to controlling DNA damage repair, LKB1 also controls ROS-induced
DNA damage via the p38 pathway142. LKB1-dependent activation of the MKK3/6-p38
cascade is required for protection against ROS-induced DNA damage and mutation and is
independent of AMPK142. LKB1 potentiates p38 signaling by maintaining the activity of
the Cdc42-PAK1 (p21 activated kinase 1) complex, thereby increasing the activity and
anti-oxidant effects of superoxide dismutase-2 and catalase142.
While it is known that IR induces ATM phosphorylation of LKB1 at Thr-366
(363 in human, 366 in mouse)143, it has been shown that LKB1 modified such that it
cannot be phosphorylated at this residue due to alanine substitution (LKB1-T363A) is
still localized to sites of DNA DSBs in an ATM/ATR-dependent fashion. It is possible
that phosphorylation of LKB1-T363 controls other aspects of LKB1 activity, but this has
yet to be directly evaluated.
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CHAPTER 2: IDENTIFICATION OF THE AMPK-RELATED KINASE HUNK AS A
SUBSTRATE OF LKB1
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ABSTRACT
LKB1, also known as Serine/threonine kinase 11 (STK11), regulates energy
homeostasis and multiple cellular functions related to carcinogenesis through its
phosphorylation and activation of adenosine monophosphate-activated protein kinase
(AMPK) and 14 AMPK related kinases (ARKs). Two additional ARKs are reportedly
not phosphorylated by LKB1 and the remaining ARK, HUNK (Hormonally Up-regulated
Neu-associated Kinase), has been predicted based on sequence homology not to be a
substrate for LKB1. Classically described as a tumor suppressor, germline loss of LKB1
causes Peutz-Jeghers syndrome, LKB1 is somatically mutated in a broad spectrum of
human cancers, and LKB1-mediated activation of AMPK and ARKs maintains cell
polarity and suppresses cell growth and proliferation. More recent evidence suggests the
existence of pro-tumorigenic roles for LKB1 in supporting tumor cell survival and
proliferation, although the LKB1 substrates mediating these roles are unclear. Here we
demonstrate that, contrary to prediction, LKB1 phosphorylates and activates HUNK, a
kinase that promotes carcinogenesis, metastasis, and tumor cell survival in a variety of
biological contexts. LKB1 activates HUNK by phosphorylation on a conserved threonine
(T222) within the T-loop and is both sufficient and required for HUNK activation in
vivo. We further demonstrate that HUNK forms a stable complex with LKB1, MO25,
and STRADβ, and does so in a manner that depends on HUNK kinase activity. These
data indicate that HUNK is a potential effector for LKB1-dependent phenotypes.
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INTRODUCTION.
LKB1 was first identified as the gene whose germline mutation and inactivation
results in Peutz-Jeghers syndrome (PJS). In addition to mucocutaneous pigmentation,
nearly half of PJS patients present with small bowel obstruction at an early age due to the
formation of benign gastrointestinal polyps that typically require repeated surgical
interventions.23,24
PJS patients also exhibit an elevated risk of cancers of the colon, rectum, breast,
small bowel, gastrointestinal tract, and pancreas17,18, with the lifetime risk of cancer as
much as 18 times higher than the general population.25 Consistent with LKB1’s
identification as a bona fide tumor suppressor, somatic mutation or deletion of LKB1
(STK11) occurs in 15-20% of lung adenocarcinomas and in 1-10% of cancers of the
ovary, bladder, cervix, pancreas, esophagus, stomach, thyroid, colon and breast.32–39
In recent years, the view of LKB1 as a classical tumor suppressor has been
complicated by evidence demonstrating that LKB1 can support tumor cell survival and
proliferation through a number of mechanisms.144 Contrary to its mutational inactivation
in the germline of PJS patients, LKB1 is amplified in pancreatic cancers, sarcomas,
adrenocortical carcinomas and gliomas145,146, forced expression of LKB1 promotes cell
viability under energy stress, and LKB1 expression is associated with poor patient
survival in hepatocellular carcinoma (HCC).56 These findings suggest that contexts may
exist in which LKB1 activation promotes cancer.
LKB1 regulates a range of cellular processes including metabolism, proliferation,
apoptosis, and polarity, exerting these effects through activation of 14 of the 17 AMPK
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related kinases (ARKs).9,10,56 Consistent with this, emerging evidence supports roles for
ARKs in promoting cancer. For example, AMPK is highly activated in as many as 40%
of human prostate cancers and is required for cell proliferation and survival in multiple
prostate cancer cell lines.73 AMPK promotes lung tumor cell survival during metabolic
stress by maintaining NADPH homeostasis, allowing cells to buffer ROS (reactive
oxygen species).69 NUAK1/ARK5 is required for the maintenance of metabolic
homeostasis and prevention of apoptosis due to collapse of cellular ATP levels in a
mouse model of MYC-driven hepatocellular carcinoma (HCC).147,148 NUAK2/SNARK
is amplified in a range of cancers, is required for melanoma cell proliferation and mTOR
activity, and its expression is associated with poor patient outcome in melanoma.149,150
Of the 17 ARKs, HUNK (Hormonally Up-regulated Neu-associated Kinase) is the
last to be experimentally evaluated as a substrate of LKB1. HUNK was originally
identified in a tumor from an MMTV-HER2/neu transgenic mouse11, suggesting a
potential role in tumorigenesis, and several lines of evidence have implicated HUNK in
the development and progression of cancers of the breast, ovary and colon.6–8 Given the
association of LKB1, HUNK and other ARKs with carcinogenesis, as well as sequence
homology among ARKs within the kinase T-loop phosphorylated by LKB1, we asked
whether LKB1 could regulate HUNK kinase activity and, thereby, whether HUNK could
be an effector of LKB1-dependent phenotypes.
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EXPERIMENTAL PROCEDURES
Immunoprecipitation kinase assays. Cells were lysed in 50 mM Tris pH 7.4,
150 mM NaCl, 10% glycerol, 1% Triton X-100, 0.5 mM EDTA, 0.5 mM EGTA, 1/100
HALT protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific). Triton
was diluted to 0.5% before combining lysates for each reaction of a given protein (batch
IP) with magnetic anti-FLAG antibody conjugated beads (SIGMA-ALDRICH) for two
hours at 4°C. Beads were washed four times with modified lysis buffer containing 0.4%
Triton X-100, washed three times in kinase reaction buffer without ATP, and then
aliquoted into separate tubes. Kinase reaction buffer was 50 mM HEPES pH 7.4, 25 mM
NaCl, 100 μM EGTA, 14.2 μM BME, 5 mM Mg(OAc)2, 100 μM ATP, 1/100 HALT
phosphatase inhibitor cocktail (Thermo Fisher Scientific), and 250 μCi/mL [γ-32P]-ATP.
One reaction omitted radioactive ATP and was used for immunoblotting. Reactions were
incubated at 30°C for 30 min, then quenched with 0.5 M EDTA (final concentration 20
mM) before mixing with 5X reducing sample buffer and boiling for 5 min at 95°C.
FLAG antibody was from Abcam, GST, LKB1, and MO25 antibodies were from Cell
Signaling, STRADα antibody was from Abnova, STRADβ antibody was from SIGMA.
Densitometry of immunoblots and radiographs was performed using ImageStudio (LICOR Biosciences).
Immunoblot analysis. Membranes were probed with peroxidase-conjugated
secondary antibodies (Jackson Laboratories) or Alexa-Fluor antibody (Molecular
Probes). Bound antibodies were detected with Luminata Classico Western HRP substrate
(Millipore) or using the Odyssey detection system (LI-COR Biosciences). The following
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primary antibodies were used during Western blotting: HUNK 6; FLAG (Abcam); GST
(Cell Signaling); LKB1 (Cell Signaling); MO25 (Cell Signaling); STRADα (Abnova);
STRADβ (SIGMA); GAPDH (Cell Signaling).
Proteins. Purified recombinant LKB1/GST-MO25/GST-STRAD (SIGMAALDRICH) was used at a final concentration of 66 ng/μL. HUNK was generated by
transient transfection of HEK-293T cells using Lipofectamine 2000 (Thermo Fisher
Scientific) according to the manufacturer’s recommendation. Mutant alleles of HUNK
were generated (GeneArt Strings, Life Technologies), double digested, and ligated into
the pBlueScript-KSII(+)-mHUNK before shuttling the modified HUNK gene into the
pK1 retroviral vector 7. TNT® Quick Coupled Transcription/Translation System
(Promega) was used following the manufacturer’s instructions.
Cell Culture. Cells were grown at 37°C in 5% CO2. HEK-293T and NAF
(Nipple Aspirate Fluid) cells were maintained in DMEM (Mediatech) supplemented with
10% FBS (Gibco), 200 nM glutamine (Gibco), and 1% penicillin/streptomycin (Gibco).
NAF cells were infected with viral particles (SIGMA-ALDRICH) generated from the
pLKO vector expressing shRNA against either LKB1 (TRCN0000024144,
TRCN0000024145, TRCN0000024146) or non-targeting control (SHC002V). After
selection with 2 ug/mL puromycin, the pLKO infected NAF cells were then infected with
pK1-FLAG-HA-mHUNK-WT viral particles.
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RESULTS

The T-Loop of HUNK exhibits moderate homology to other AMPK family kinases.
LKB1 phosphorylates a conserved threonine within the T-loop of multiple ARKs
to increase kinase activity (Figure 3A). LKB1 also phosphorylates a conserved serine
residue at +4 in MARKs 1, 2 and 3 9. Members of the ARK family show strong
conservation of amino acid residues surrounding the LKB1 phosphorylation site, with all
fourteen previously identified LKB1 ARK substrates exhibiting perfect conservation at 2, +2, +3, and +4 (Figure 3B).
Inspection of the sequences of ARKs surrounding the conserved threonine
phosphorylated by LKB1 fails to reveal any obvious basis for distinguishing the 14
LKB1-regulated kinases from the two ARKs, NIM1 and MELK, not regulated by LKB1.
However, the absence of LKB1 regulation of NIM1 and MELK appears to result from the
ability of these kinases to autophosphorylate this conserved T-loop threonine 9,10. The
single remaining ARK for which LKB1 regulation had not previously been tested,
HUNK, possesses each of the conserved T-loop residues at +2, +3 and +4, but is the only
ARK lacking conservation of the leucine at -2, which is replaced by phenylalanine –
another large hydrophobic residue. In addition, HUNK is the only ARK with a glutamine
residue at +1. Based on this lower degree of sequence homology relative to other ARKs,
it has been predicted that HUNK would not be a substrate for LKB1 10,62. Nevertheless,
alignment data remain compatible with the possibility that HUNK is an LKB1 substrate 9.
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Figure 3. The T-loop of HUNK has moderate homology with other AMPK family
kinases. (A) AMPK family tree of human kinases. NIM1 and MELK are not regulated
by LKB1 and are indicated in red. (B) Alignment of T-loop residues of AMPK family
members. As NIM1 and MELK are not regulated by LKB1, they were omitted from
generation of the consensus sequence. The large * indicates the conserved threonine
phosphorylated by LKB1 in each of the kinases listed in black. The small * indicates the
serine phosphorylated in MARKs 1-3 by LKB1.
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LKB1 phosphorylates T222 of HUNK and stimulates HUNK kinase activity.
To determine whether HUNK is regulated by LKB1 phosphorylation, we
generated an alanine substitution mutant of HUNK lacking the T-loop threonine
conserved within LKB1 substrates (T222A). As negative controls, we compared the
activity of WT HUNK and T222A HUNK both to a kinase-dead allele of HUNK in
which lysine 91 within the HUNK ATP-binding domain is substituted with methionine
(K91M), and to an empty vector control 6.
Lysates from HEK-293T cells transiently transfected with the corresponding
FLAG-HUNK vectors were batch immunoprecipitated using anti-FLAG antibodies
conjugated to magnetic beads and kinase reactions were performed, with or without
addition of purified recombinant LKB1/MO25/STRAD to the reaction. Anti-FLAG
beads from each immunoprecipitation reaction were evenly divided between eight kinase
reactions. Six reactions used [γ-32P]-ATP to generate autoradiographs, three with and
three without recombinant LKB1. Two reactions did not use [γ-32P]-ATP, one with and
one without LKB1, and were used for immunoblotting. The relative specific activity of
HUNK phosphorylation in each reaction was calculated in the presence or absence of
recombinant LKB1/MO25/STRAD.
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Figure 4. LKB1 phosphorylates T222 of HUNK to increase HUNK kinase activity.
Immunoprecipitation kinase assay using [γ-32P]-ATP and anti-FLAG antibodyconjugated magnetic beads. FLAG-tagged HUNK mutants were expressed by transient
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transfection of HEK-293T cells. (A) Autoradiographs from immunoprecipitation kinase
assays. (B) Western blot for FLAG-tagged HUNK and GST-fusions of MO25 and
STRAD in immunoprecipitation kinase reactions. (C) Relative HUNK specific activity
as measured by densitometry of HUNK in autoradiographs, normalized to HUNK
expression from the anti-FLAG blot with wild type HUNK activity in the absence of
recombinant LKB1 set to 100%. Quantified levels are shown as means +/- standard
deviation of three reactions performed in parallel. Data are representative of two separate
experiments.

P a g e | 35
Wild type HUNK showed greater signal in the autoradiographs than any other
mutant (Figure 4). WT also showed an altered distribution in both autoradiograph and
immunoblot, displaying a basal band similar to that found in T222A and K91M, and
showing signal in a region of lower electrophoretic mobility. Addition of LKB1 to the
WT reaction increased total phosphate on HUNK throughout the band in the
autoradiograph, and LKB1 increased HUNK in the lower mobility region of the
immunoblot, suggesting that LKB1 activates HUNK as it does the other ARKs. As this
region of lower mobility HUNK is increased in vitro by recombinant LKB1 and is only
present in the WT reactions, it is most likely due to increased HUNK kinase
autophosphorylation resulting in a hyperphosphorylated region of protein.
Residual HUNK phosphorylation, above background in Empty vector lanes, was
observed for the K91M and T222A mutants. However, the lower mobility region of
phosphate signal on HUNK was not observed for kinase reactions involving these alleles,
irrespective of LKB1 addition, suggesting that these mutants have reduced kinase
activity. In the absence of LKB1 addition, the T222A allele displayed 2.6 times the
phosphorylation of K91M HUNK, indicating greater basal activity for the T222A mutant.
However, upon addition of LKB1, phosphorylation of K91M increased twelve-fold,
whereas T222A phosphorylation increased only three-fold, resulting in twice as much
phosphate deposited on K91M as on T222A (Figure 4). This is consistent with a model
in which the T222A mutation results in loss of the major site of LKB1 phosphorylation of
HUNK, and a failure of LKB1-induced HUNK activation.
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The increased phosphorylation of WT HUNK as compared to T222A, in the
absence of recombinant LKB1, may reflect a difference in LKB1 activation of HUNK in
the cells from which HUNK was immunoprecipitated, which would predict that the loss
of LKB1 activity in these cells would lead to a loss of HUNK activity
immunoprecipitated from those cells, a prediction we confirmed in subsequent
experiments.

LKB1 phosphorylation of HUNK outside the T-loop fails to increase kinase activity.
In the previous experiment, we saw that while LKB1 could not induce production
of a hyperphosphorylated band on the T222A mutant of HUNK, it could increase
phosphorylation of the basal band, suggesting phosphorylations at residues other than the
conserved threonine, possibly outside of the T-Loop. To investigate the extent of LKB1
phosphorylation of HUNK outside of the T-loop, we generated FLAG-tagged alanine
substitution mutants of HUNK lacking one (S217), three (S217/S221/T222), or all five
(S208/S217/S221/T222/S226)) of the serine and threonine residues within the T-Loop,
hereafter referred to as mutants 1A, 3A, and 5A (Figure 5). If the 5A mutant is
phosphorylated by LKB1, those events must be occurring at residues outside of the TLoop. We generated these mutants on either a WT or K91M (kinase dead) background,
expressed each by transient transfection of HEK-293T cells, and performed
immunoprecipitation kinase assays on lysates from each transfection .
As predicted, all three K91M-based alleles of HUNK (K91M-1A, - 3A, -5A)
exhibited lower levels of phosphorylation than the corresponding WT alleles of HUNK
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(WT-1A, -3A, -5A) in the absence of LKB1, and none of the K91M alleles exhibited a
hyperphosphorylated band in the presence of LKB1 (Figure 5). In contrast to the K91M
mutation, alanine substitution at S217 of HUNK (WT-1A) did not impair basal activity of
HUNK, the extent of LKB1-induced phosphorylation, or the formation of a
hyperphosphorylated band in response to LKB1 addition (Figure 5). This suggests that
the S217A mutation impairs neither basal, nor LKB1-stimulated, HUNK activity.
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Figure 5. LKB1 phosphorylation of HUNK outside the T-Loop fails to activate
HUNK. Immunoprecipitation kinase assays using [γ-32P]-ATP and anti-FLAG antibodyconjugated magnetic beads. FLAG-tagged HUNK mutants were expressed by transient
transfection of HEK-293T cells. (A) Western blot for FLAG-tagged HUNK and GSTfusion MO25 and STRAD in immunoprecipitation kinase assays. (B) Autoradiographs
from immunoprecipitation kinase assays. (C) Relative HUNK specific activity as
measured by densitometry of HUNK in autoradiographs, normalized to HUNK
expression from the anti-FLAG blot with wild type HUNK activity in the absence of
recombinant LKB1 set to 100%. Data are representative of two experiments, each
performed without replicate reactions.
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Consistent with the presence of an alanine substitution at T222 in WT-3A and
WT-5A, basal phosphorylation of these HUNK alleles was reduced in the absence of
LKB1, and LKB1 addition induced only a two-fold increase in phosphate on these alleles
(Figure 5), similar to that observed for the T222A single mutant (Figure 4). In addition,
neither the WT-3A nor WT-5A mutants exhibited a hyperphosphorylated band in the
presence or absence of LKB1, consistent with an inability of LKB1 to activate alleles of
HUNK lacking T222.
As before, alleles of wild type HUNK bearing the T222A substitution (WT-3A, 5A) showed a modest reduction in basal phosphorylation compared to WT and WT-1A
alleles of HUNK in the absence of exogenously added recombinant LKB1 heterotrimer,
that remained higher than those observed for K91M alleles of HUNK (Figure 5). In
contrast, alleles of K91M HUNK bearing the T222A substitution (K91M-3A, -5A)
exhibited levels of basal phosphorylation that were similar to those of K91M alleles
lacking the T222A substitution (K91M, K91M-1A). This observation is consistent with
the possibility that the higher residual levels of basal phosphorylation exhibited by WT
HUNK alleles retaining T222 compared to HUNK K91M alleles is due to HUNK
activation by endogenous LKB1.
Notably, while basal HUNK phosphorylation was greater for the WT-3A and
WT-5A alleles than for the K91M-3A and K91M-5A alleles, all achieved similar levels
of phosphorylation upon addition of LKB1 (Figure 5). Since the WT-5A and K91M-5A
alleles do not contain serine or threonine residues within their respective T-loops, this
implies that the LKB1-induced increase in phosphorylation observed for these alleles
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reflects an increase in phosphate deposited during the kinase reaction by LKB1 outside of
the T-loop of HUNK. However, since none of these alleles exhibits a
hyperphosphorylated band in the presence of LKB1, or an overall level of
phosphorylation exceeding that of WT HUNK in the absence of LKB1, these findings
suggest that LKB1 phosphorylation outside of the T-loop of HUNK has little effect on
kinase activity.

LKB1 activates HUNK in a reconstituted system in vitro.
To extend our findings regarding LKB1 activation of HUNK, in vitro translated
HUNK-WT, HUNK-K91M, or empty vector control was used as input for
immunoprecipitation kinase assays with and without addition of recombinant LKB1
heterotrimer (Figure 6). Consistent with our prior results, in the absence of LKB1 a
hyperphosphorylated form of HUNK was evident for HUNK-WT, but not HUNK-K91M,
indicating that wild type HUNK has intrinsic basal activity (Figure 6). In the presence of
LKB1, both WT and K91M HUNK exhibited a basal phosphorylated band of equivalent
intensity, whereas only WT HUNK exhibited a hyperphosphorylated band, and this band
was markedly enhanced by LKB1 addition. This indicates that LKB1 can activate WT
HUNK in vitro in the absence of factors that might otherwise co-immunoprecipitate with
HUNK from cell lysates.
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Figure 6. LKB1 activates in vitro translated HUNK. Immunoprecipitation kinase
assay using [γ-32P]-ATP and anti-FLAG antibody-conjugated magnetic beads. FLAGHUNK mutants were expressed using TNT® Quick Coupled Transcription/Translation
System. (A) Autoradiograph from immunoprecipitation kinase assays. (B) Western blot
for FLAG-HUNK and GST-MO25 and GST-STRAD in immunoprecipitation kinase
assays. (C) Relative HUNK specific activity as measured by densitometry of HUNK in
autoradiographs, normalized to HUNK expression from the anti-FLAG blot with wild
type HUNK activity in the absence of recombinant LKB1 set to 100%. Single
experiment.
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LKB1 controls HUNK activation in vivo.
We next asked whether LKB1 activity is a physiologically significant determinant
of HUNK activity in cells. As activation of LKB1 requires complex formation 50, we
hypothesized that up-regulating expression of the LKB1/MO25/STRAD heterotrimer
would be sufficient to increase LKB1 activity in cells and would, in turn, result in
increased activation of HUNK. Conversely, we hypothesized that down-regulating
LKB1 activity in cells by expressing the dominant negative, kinase-inactive mutant of
LKB1, D194A 61, would result in decreased activation of HUNK.
To test this hypothesis, HEK-293T cells were simultaneously transfected with
expression vectors for HUNK, LKB1 (WT or D194A), MO25 and STRAD. Control cells
were transfected with a vector encoding HUNK, but not vectors encoding the LKB1
heterotrimer. Kinase assays were performed using HUNK immunoprecipitated from
each of these cell lysates.
As before, a hyperphosphorylated band was observed for WT HUNK
immunoprecipitated from HEK-293T cells in the absence of expression of exogenous
LKB1 (Figure 7). Consistent with our prior kinase assays using recombinant
LKB1/MO25/STRAD, cells transfected with vectors encoding HUNK and wild type
LKB1/MO25/STRAD exhibited a four-fold increase in HUNK phosphorylation,
predominantly within the hyperphosphorylated band. In contrast, HUNK from cells
transfected with dominant negative LKB1-D194A showed a four-fold reduction in the
hyperphosphorylated form of HUNK (Figure 7). These data provide additional evidence
supporting the phosphorylation and activation of HUNK by LKB1, and further suggest
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that basal HUNK activity (i.e., HUNK activity in the absence of exogenously added
LKB1) in mammalian cells may reflect activation by endogenous LKB1.

P a g e | 44

Figure 7. LKB1 controls HUNK activation in vivo. Immunoprecipitation kinase assay
using [γ-32P]-ATP and anti-FLAG antibody-conjugated magnetic beads. FLAG-HUNK,
HA-LKB1, HA-MO25, and HA-STRAD were simultaneously transfected into HEK293T cells. (A) Autoradiographs from immunoprecipitation kinase assays. (B)
Immunoblot for FLAG-HUNK in immunoprecipitation kinase reactions. (C)
Immunoblot for LKB1 in lysates from which HUNK was immunoprecipitated. (D)
Relative HUNK specific activity as measured by densitometry of HUNK in
autoradiographs, normalized to HUNK expression from the anti-FLAG blot with wild
type HUNK activity in the absence of recombinant LKB1 set to 100%. Single
experiment.
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Endogenous LKB1 is required for HUNK activation in cells.
We next asked whether endogenous LKB1 is required for HUNK kinase activity
in cells. We stably expressed shRNAs against LKB1 or a scrambled control hairpin in
NAF cells, a mouse MMTV-neu cell line known to have a high level of basal HUNK
activity 7.
Consistent with our observations following transfection of a dominant-negative, kinasedead allele of LKB1, HUNK from lysates from cells in which LKB1 was knocked down
exhibited a reduction in HUNK activity, compared to control shSCR cells (Figure 8).
This further supports the hypothesis that endogenous LKB1 is required for HUNK
activation in cells.

WT HUNK Binds LKB1, MO25, and STRADβ but not STRADα.
Given our identification of HUNK as a substrate for the LKB1 complex, we
sought to determine whether HUNK forms a stable complex with the LKB1 heterotrimer
by co-immunoprecipitation assays from mammalian cells. FLAG-tagged HUNK was
expressed by transient transfection in 293T cells, then immunoprecipitated using antiFLAG antibody conjugated magnetic beads. This revealed that WT HUNK stably bound
to LKB1, MO25, and STRADβ but not to STRADα (Figure 9).

P a g e | 46

Figure 8. LKB1 is required for HUNK kinase activity in vivo. Immunoprecipitation
kinase assay using [γ-32P]-ATP and anti-FLAG antibody conjugated magnetic beads.
Endogenous HUNK was immunoprecipitated from NAF cells which were infected with
vectors expressing shRNA against LKB1 or a scrambled control hairpin. (A)
Autoradiograph from immunoprecipitation kinase assay. (B) Immunoblots for HUNK in
an immunoprecipitation kinase assay and for LKB1 in crude lysates from which HUNK
was immunoprecipitated. (C) Relative specific activity as measured by densitometry of
HUNK in both blot and autoradiograph. Single experiment.
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Figure 9. WT HUNK binds LKB1, MO25, and STRADβ but not STRADα. Coimmunoprecipitation assay using anti-FLAG antibody conjugated magnetic beads.
FLAG-HUNK mutants were expressed by transient transfection of HEK-293T cells.
Single experiment.

P a g e | 48
DISCUSSION
We have shown for the first time that LKB1 phosphorylates and regulates the
AMPK-related kinase, HUNK. Specifically, our in vitro and in vivo data indicate that
LKB1 phosphorylates HUNK at a conserved threonine (T222), resulting in substantial
increases in HUNK kinase activity. In addition, experiments using in vitro translated
HUNK suggested that LKB1 phosphorylation of HUNK requires only the components of
the LKB1 heterotrimer. Further data indicated that while LKB1 can phosphorylate
HUNK in vitro at residues outside the T-loop, these sites do not appear to contribute to
the LKB1-mediated regulation of HUNK activity. HUNK exhibited some basal activity
in the absence of exogenously added LKB1, including in vitro translation experiments,
however this may be attributable – at least in part – to endogenous LKB1 activity, since
transfection of dominant-negative LKB1 into cells resulted in decreased HUNK kinase
activity. Finally, our results reveal that LKB1 is required for HUNK activity in vivo as
knockdown of endogenous HUNK significantly reduces HUNK kinase activity.
It has been previously been proposed that a leucine at -2 might be required for
LKB1 phosphorylation of ARK substrates10,62. However, since HUNK has a
phenylalanine residue at -2, this may indicate that other large, hydrophobic residues at
this position may suffice. In this regard, it has been reported that LKB1 phosphorylates
p53, PAK1, and PTEN at peptide sequences that share little homology with ARK T-loop
sites133–135. This suggests that LKB1 substrate selection may be less restricted than
originally suspected. As such, it is possible that other substrates of LKB1 exist that also
lack the leucine at -2, although it is known that several kinases (TSSK1-4, SSTK) that
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lack all conserved T-Loop residues N-terminal to the conserved threonine are not
regulated by LKB110.
Multiple lines of evidence implicate HUNK in promoting the development and
progression of cancers in a variety of contexts. For example, HUNK expression is
significantly higher in aggressive subsets of human cancer, including lymph node
positive breast cancers, HER2/neu-expressing breast cancers, and poorly differentiated
cancers of the breast, ovary, and colon6. Consistent with a functional role for HUNK in
tumorigenesis, HUNK is required for primary mammary tumor formation in mouse
models of breast cancer driven by HER2/neu overexpression or PTEN deletion7,8, and
HUNK is required for the metastasis of mammary tumors driven by c-MYC6.
The realization that LKB1 activates HUNK raises the possibility that HUNK may
serve as an effector for LKB1-dependent tumor suppressive phenotypes. In this regard,
some reports have implicated HUNK in the negative regulation of proliferation of
intestinal epithelial cells and in the suppression of metastasis of basal-subtype breast
cancer cells151,152. However, in light of demonstrated roles for HUNK in promoting the
development and progression of cancers in a variety of contexts6–8, a perhaps more
interesting possibility is that HUNK may serve as an effector for LKB1-dependent
phenotypes that promote cancer cell survival and tumor progression, for which recent
evidence has emerged56,144,153.
In this regard, there are several LKB1-dependent phenotypes for which the
effectors responsible have yet to be elucidated. For example, recent work has uncovered
links between LKB1 and the DNA damage response (DDR), whereby LKB1 controls
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BRM-dependent non-homologous end joining, and cells deficient for LKB1 exhibit
marked increases in chromosomal aberrations140. In an analogous manner, LKB1
haploinsufficient mice show dramatically increased sensitivity to UVB-induced skin
cancer, and both these mice and LKB1-deficient human keratinocytes exhibit impaired
repair of UVB-induced DNA damage141. LKB1 reduces mutation rate and increases
survival after DNA damage by stimulating BRCA1 expression in an at least partially
AMPK-dependent manner138. Whether HUNK may play a role in mediating effects of
LKB1 on DNA damage responses remains to be determined.
Furthermore, there are mechanistically unexplained links between LKB1 and
TGF-β signaling. TGF-β, like LKB1, has been reported to function as a tumor suppressor
during early stages of tumorigenesis, but as a tumor promoter in later stages of
tumorigenesis154,155. The gastrointestinal tracts of mice deficient for stromal LKB1 form
polyps indistinguishable from PJS polyps156. While LKB1-/- stromal cells exhibit
unperturbed mTOR, AMPK, SRF, RhoA, and FAK signaling157, they produce less TGFβ, a defect which results in increased proliferation of epithelial cells in both murine and
human PJS tissues158. As both HUNK and TGF-β have been shown to down-regulate
MYC expression8, it is intriguing to speculate that HUNK may play a role in mediating
the relationship between LKB1 and TGF-β signaling.
Our findings that wild type HUNK binds to the LKB1 heterotrimer far more
efficiently than does HUNK-K91M, and that wild type HUNK binds heterotrimeric
complexes with STRADβ, but not STRADα, raises at least three questions. First, why
does HUNK-WT bind STRADβ but not STRADα? Much of the literature on LKB1 does
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not differentiate between STRAD isoforms, which may neglect important aspects of
regulation of LKB1 signaling. STRADα is known to promote the activation and nuclear
export of LKB1/MO25, whereas STRADβ can activate LKB1 but does not appear to
affect its subcellular localization, potentially allowing activated LKB1 to remain in the
nucleus51. As HUNK-WT, STRADα, and STRADβ can each be found in the nucleus as
well as in the cytoplasm51,159, the differential binding of HUNK to STRADα and
STRADβ may be due either to structural differences between the STRAD isoforms that
influence HUNK binding, or to scaffolds or chaperones found only in the nucleus.
Second, why does HUNK-K91M fail to bind the LKB1 heterotrimer? One
possible explanation is that binding occurs in the nucleus, from which HUNK-K91M is
excluded159. Another possibility is that STRADβ binding to HUNK may occur at sites
created by HUNK autophosphorylation. To our knowledge, our data are the first to
suggest that kinase activity of an LKB1 substrate may alter binding to LKB1.
Third, does HUNK binding to the nuclear specific complex of
LKB1/MO25/STRADβ affect its nuclear/cytoplasmic distribution? Such binding has
been seen to alter distribution in the case of the orphan nuclear receptor Nur77, with the a
resulting reduction in AMPK activation60. It is possible that HUNK stabilizes LKB1 in a
complex that is localized to the nucleus, thus altering compartment specific activity of the
LKB1 heterotrimer.
In conclusion, we show that HUNK is phosphorylated and activated by LKB1 in
vivo and in vitro, and thereby identify HUNK as a potential mediator of LKB1-dependent
effects. This possibility is consistent with the emerging appreciation of tumor promoting
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effects of LKB1, and the demonstration that HUNK can promote tumorigenesis and
tumor cell survival in multiple biological contexts. Our data additionally suggest the
value of further investigation into the potential roles of HUNK as an LKB1 effector in the
contexts of tumor suppression, control of TGF-β signaling, and regulation of DNA
damage repair, and raise the possibility that different isoforms of STRAD may have
differential impacts on LKB1-mediated signal transduction.
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CHAPTER 3: IDENTIFICATION OF CHK2 AND CAMKKβ AS
SUBSTRATES OF HUNK
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ABSTRACT.
To identify substrates of HUNK kinase, we performed kinase assays on protein
microarrays and compared results for arrays treated with WT or K91M (kinase dead)
HUNK to generate a ranked list of candidate substrates. To date, we have used
immunoprecipitation kinase assays to confirm two substrates, CAMKKβ and CHK2.
CAMKKβ and HUNK phosphorylate each other, and this interaction does not alter kinase
activity of CAMKKβ. We also showed that HUNK is required for efficient activation of
the ATM/CHK2 pathway in response to DNA damage in cells.

INTRODUCTION.
There are over 500 human kinases representing about 1.7% of all human genes
and, together, these enzymes mediate much of the signal transduction in eukaryotic cells2.
Further, by altering the activity of catalytic enzymes, kinases control diverse cellular
processes, and mutation of kinases underlies many human diseases160. The primary mode
of control is phosphorylation of substrates, thus knowledge of which substrates a kinase
phosphorylates provides insight into its function.
There are many methods for identification of kinase substrates. Chemical
genetics, also known variously as the bump kinase, Shokat kinase, or analog specific
approach, requires mutating the active site of the kinase so it can accept an analog of
ATP modified with a bulky alkyl moiety that makes unaltered kinases unable to catalyze
phosphotransfer161. This approach has several elegant variations, but all depend on being
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able to mutate the kinase of interest while retaining kinase activity. HUNK did not meet
this requirement (data not shown), so other approaches were sought.
Phage display allows the screening of many proteins or peptides at once through
phosphorylation of material displayed on the surface of transfected bacteria162. Several
variations of screens based on identifying candidate substrates through their binding to
the kinase of interest exist, but the binding between kinase and substrate is often
transient, and these methods are prone to false positives as they identify binding partners
and complex members as candidate substrates163.
There are a multitude of approaches using mass spectrometry, including stable
isotope labeling by amino acids in cell culture (SILAC), in which experimental cells are
grown in media lacking an essential amino acid but supplemented with a non-radioactive,
isotopically labeled form of that amino acid164. Experimental cells must also have altered
activity in the kinase of interest, which can be achieved through various means including
overexpression, knockout, knockdown, or chemical inhibition. Lysates from
experimental cells are combined with lysates from control cells grown in standard media
and the mass shift between their resulting mass spectra identify candidate substrates.
Another approach involves performing a kinase assay on a chip coated with either
peptides or proteins. This requires that the kinase of interest first be purified, ideally
along with a kinase dead control. This is the approach we took to identify substrates of
HUNK kinase. We performed kinase assays on protein microarrays and compared the
results when the arrays were treated with WT or K91M (kinase dead) HUNK to generate
a ranked list of candidate substrates.
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Genetic evidence from HUNK-deficient mice has shown multiple roles for
HUNK in the development and progression of cancers of the breast, ovary and colon6–8,
in part by negatively regulating apoptosis. HUNK is also linked to Akt and PTEN
dependent effects, in particular control of apoptosis in the involuting mammary gland, in
which forced overexpression of Akt rescues excessive apoptosis induced by HUNK
deletion8. These data provide hints as to possible effectors of HUNK kinase, framing
our search for HUNK substrates.
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EXPERIMENTAL PROCEDURES

Buffers:
M2 Lysis Buffer (M2LB): 50 mM Tris pH 7.4, 150 mM NaCl, 10% glycerol, 1%
Triton X-100, 0.5 mM EDTA, 0.5 mM EGTA, 1/100 HALT inhibitor cocktail (Thermo
Fisher Scientific).
M2 High Salt Wash (M2HSW): 50 mM Tris pH 7.4, 500 mM NaCl, 0.4% Triton
X-100, 0.5 mM EDTA, 0.5 mM EGTA, 1/100 HALT inhibitor cocktail (Thermo Fisher
Scientific).
M2 Binding Buffer (M2BB): 50 mM Tris pH 7.4, 150 mM NaCl, 0.4% Triton X100, 0.5 mM EDTA, 0.5 mM EGTA, 1/100 HALT inhibitor cocktail (Thermo Fisher
Scientific).
M2 Dilution Buffer (M2DB): 50 mM Tris pH 7.4, 150 mM NaCl, 0.0% Triton X100, 0.5 mM EDTA, 0.5 mM EGTA, 1/100 HALT inhibitor cocktail (Thermo Fisher
Scientific).
HUNK Kinase Buffer (HKB): 25 mM HEPES pH 7.4, 0.1% TX-100, 1 mM DTT,
0X HALT, 25 mM NaCl, 2.5 mM Mg(OAc)2.
Tandem Affinity Tag Purification. Cells were lysed in 50 mM Tris pH 7.4, 150
mM NaCl, 10% glycerol, 1% Triton X-100, 0.5 mM EDTA, 0.5 mM EGTA, 1/100
HALT protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific), then snap
frozen on dry ice/ethanol for later processing.
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Lysates were thawed while inverting tubes to mix, then Triton X-100 was diluted
to 0.5%. Diluted lysates were incubated with anti-FLAG antibody conjugated beads for
two hours at 4°C while being rotated. Beads were then washed three times with M2BB,
then eluted three times with 150 ng/uL 3XFLAG peptide (SIGMA-ALDRICH) in M2BB.
Eluates were then incubated with anti-HA antibody conjugated beads for two hours at
4°C while being rotated. Beads were then washed three times with M2BB, then eluted
three times with 1000 ng/uL HA peptide (SIGMA-ALDRICH) in M2HSW. Eluted
protein was frozen for later use on dry ice/ethanol.
Before use in kinase assays, protein was thawed while inverting tubes to mix, then
placed in 500 uL 10 kD MW cut off centrifugal concentrator (Millipore). Three times the
protein was concentrated to ~20 uL then diluted with HKB. IP kinase assays were used
to assess the activity of the protein using anti-HA antibody conjugated beads, 100 uM
ATPγS, and the immunofluorescent approach described in the kinase assay on protein
microarrays.
Protein microarray kinase assays with ATPγS and immunofluorescence.
ProtoArrays V5 (Thermo Fisher Scientific) were warmed from -20°C to 4°C for one
hour, then blocked for one hour with 0.22 um filtered 1X PBS pH 7.4 (Thermo Fisher
Scientific) with 1% protease-free BSA (SIGMA-ALDRICH). 120 uL reaction mixture
derived from 2 ug purified and buffer exchanged HUNK in HKB with 100 uM ATPγS
was added to each microarray, then the array was gently covered with a 50 mm coverslip
and incubated at 30°C for 2 hours. Arrays were washed twice for 15 minutes with 0.5%
SDS, then three times for 3 minutes in 1X PBS-T (0.05% Tween-20). Added 120 uL 2.5
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mM PNBM (p-nitrobenzylmeslyate) in 1X PBS, coverslipped, and incubated 2.5 hours at
room temperature.
Arrays were washed 3 times for 3 minutes in 1X PBS-T. 120 uL antithiophosphate ester (Abcam) in PBS-T and coverslip were added to arrays and they were
incubated overnight at 4°C. Slides were washed 4 times in PBS-T and then 120 uL goatanti-rabbit-Cy3 (Invitrogen) and coverslip were added and arrays were incubated for 2
hours at room temperature. Arrays were washed 5 times in PBS-T, rinsed three times in
water, and spun dry in slide holders at 1000 RPM. Arrays were imaged on a GenePix
4000. Quantifications were exported to excel and a linear regression line calculated
giving predicted values on the HUNK-WT treated array as a function of values from the
HUNK-K91M treated array.
Immunoprecipitation kinase assays. Cells were lysed 50 mM Tris pH 7.4, 150
mM NaCl, 10% glycerol, 1% Triton X-100, 0.5 mM EDTA, 0.5 mM EGTA, 1/100
HALT protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific). Triton
was diluted to 0.5% before combining lysates for each reaction of a given protein (batch
IP) with magnetic anti-FLAG antibody conjugated beads (SIGMA-ALDRICH) for two
hours at 4°C. Beads were washed four times with modified lysis buffer containing 0.4%
Triton X-100, washed three times in kinase reaction buffer without ATP, and then
aliquoted into separate tubes. Kinase reaction buffer was 50 mM HEPES pH 7.4, 25 mM
NaCl, 100 μM EGTA, 14.2 μM BME, 5 mM Mg(OAc)2, 100 μM ATP, 1/100 HALT
phosphatase inhibitor cocktail (Thermo Fisher Scientific), and 250 μCi/mL [γ-32P]-ATP.
One reaction omitted radioactive ATP and was used for immunoblotting. Reactions were
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incubated at 30°C for 30 min, then quenched with 0.5 M EDTA (final concentration 20
mM) before mixing with 5X reducing sample buffer and boiling for 5 min at 95°C.
FLAG antibody was from Abcam, GST, LKB1, and MO25 antibodies were from Cell
Signaling, STRADα antibody was from Abnova, STRADβ antibody was from SIGMA.
Densitometry of immunoblots and radiographs was performed using ImageStudio (LICOR Biosciences). [γ-18O4]-ATP (Cambridge Isotope Laboratories, >94% 18O on γphosphate) was used at 100 uM and was the only ATP source used in kinase assays
analyzed by mass spectrometry.
Immunoblot analysis. Membranes were probed with peroxidase-conjugated
secondary antibodies (Jackson Laboratories) or Alexa-Fluor antibody (Molecular
Probes). Bound antibodies were detected with Luminata Classico Western HRP substrate
(Millipore) or using the Odyssey detection system (LI-COR Biosciences). The following
primary antibodies were used during Western blotting: HUNK 6; FLAG (Abcam); GST
(Cell Signaling); LKB1 (Cell Signaling); MO25 (Cell Signaling); STRADα (Abnova);
STRADβ (SIGMA); GAPDH (Cell Signaling).
Proteins. HUNK was generated by stable infection of NAF cells with pK1FLAG-HA-mHUNK-WT, pK1-FLAG-HA-mHUNK-K91M, or pK1-Empty viral
particles. CAMKKβ-K194A and CHK2-K249R kinase dead proteins were generated by
transient transfection of 293T cells with pK1-FLAG-HA expression vectors.
Cell Culture. Cells were grown at 37°C in 5% CO2. HEK-293T and NAF cells
were maintained in DMEM (Mediatech) supplemented with 10% FBS (Gibco), 200 nM
glutamine (Gibco), and 1% penicillin/streptomycin (Gibco). NAF cells were infected
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with viral particles (SIGMA-ALDRICH) generated from the pLKO vector expressing
shRNA against either LKB1 (TRCN0000024144, TRCN0000024145,
TRCN0000024146) or non-targeting control (SHC002V). After selection with 2 ug/mL
puromycin, the pLKO infected NAF cells were then infected with pK1-FLAG-HAmHUNK-WT viral particles.
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RESULTS

Tandem Affinity Tag Purification of HUNK from NAF Cells.
NAF cells are derived from a tumor in an MMTV-HER2/neu mouse and have
been demonstrated to express high levels of HUNK protein12. These cells were infected
with retroviral particles to constitutively express FLAG-HA-mHUNK-WT and FLAGHA-mHUNK-K91M, as well as empty vector. HUNK-K91M was used throughout as a
control for co-immunoprecipitating kinase activity.
The scheme used for purification and evaluation of HUNK is shown below
(Figure 10). Purification used two different affinity tags, FLAG and HA, and kinase
activity and protein purity were evaluated before and after the purification.
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Figure 10. Scheme for Tandem Affinity Tag Purification of FLAG-HA-mHUNK
from NAF Cell Lysate. Briefly, cells were lysed using Triton X-100, lysates were
bound to and eluted from antibody conjugated beads, and the activity and purity of the
resulting protein was evaluated via silver stain and IP kinase assay.
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Purification resulted in very high loss of starting material but yielded protein of
high apparent purity when inspected on a silver stained gel (Figure 11). The final yield
was about 4% with the dominant band running at the same electrophoretic mobility as the
HA-tag on HUNK shown in the immunoblot.
The activity of the protein was assessed via immunoprecipitation kinase assay
(IPKA) on anti-HA antibody conjugated beads, using ATPγS and immunofluorescence
(Figure 12). This approach was developed in the lab of Kevan Shokat and it uses ATPγS
to thiophosphorylate kinase substrates in kinase reactions165. After the kinase reaction,
thiols present are alkylated using the agent PNBM (p-nitrobenzylmesylate), and then the
thiophosphate ester is detected using a rabbit monoclonal antibody. While not all
enzymes are capable of catalyzing thiophosphorylation of substrate165, many, including
HUNK, are.
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Figure 11. Silver Stain and Anti-HA-tag Western Blot from Tandem Affinity Tag
Purification of FLAG-HA-mHUNK from NAF Cell Lysate. Silver stain showing
purity of protein at each stage. HA-tag immunoblot showing relative HUNK protein at
each stage of purification.
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Figure 12. Schematic for Kinase Assay using ATPγS and Immunofluorescence.
Substrates are thiophosphorylated using ATPγS, then alkylated using PNBM. The
resulting thiophosphate ester is detected using a rabbit monoclonal antibody.

The thiophosphate IPKA was used to compare the activity of the HUNK in the
crude lysates to that present in the purified protein (Figure 13). The ratio of
thiophosphate to HA-tag was calculated as a measure of relative activity of the kinase in
the IP. This ratio dropped roughly forty-fold during the purification, indicating much of
the activity of the kinase was lost during purification. The ratio of WT to K91M relative
activity decreased from 5 to 2, indicating that the final purified HUNK was yielding
thiophosphate signal only twice as strong as the negative control K91M. It is worth
noting that the due to the workflow used, protein input amounts were not normalized and
the amount of protein input was less for the post-purification samples. This may have
lowered the apparent activity of the purified protein, as we know that signal in the IPKA
correlates with amount of protein on the beads (data not shown). This protein from this
purification was used for kinase assays on the protein microarrays.
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Figure 13. Immunoprecipitation kinase assay to evaluate activity of HUNK kinase
before and after purification. Briefly, NAF lysates or purified HUNK were
immunoprecipitated, washed, and subjected to a kinase assay using ATPγS and
immunofluorescence. Single experiment.
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Immunoprecipitation Kinase Assay on Protein Microarrays Using ATPγS and
Immunofluorescence.
ProtoArrays (V5, Thermo Fisher Scientific) were used to search for substrates of
HUNK. ProtoArrays are protein microarrays containing roughly 9,000 unique proteins.
Proteins are expressed in insect cells as GST fusions and are placed in adjacent duplicate
spots on a coated glass slide. The spots are arranged in 48 blocks, each with recurring
controls including autophosphorylating kinases and fluorescent spots.
We performed kinase assays on ProtoArrays, treating one chip each with HUNKWT and HUNK-K91M. The chips were imaged on a GenePix 4000 (Figure 14), the
values were exported to excel and plotted spot vs. spot (Figure 15). A linear regression
line was calculated as Predicted_WT_Value = m * K91M_Value + b. If the actual value
for WT was greater than or equal to 4 * Predicted_WT_Value, and the two values for WT
were similar, the protein in question was deemed a candidate substrate for HUNK (Table
2). If the actual value for WT was less than or equal to 0.25 * Predicted_WT_Value, the
protein in question was highlighted on the chart (Figure 15).
20 candidates were identified (two were CAMKKβ), including 8 kinases and 3
MAPK pathway members. 22 proteins and 4 paired control spots had values for WT that
were less than or equal to 0.25 * Predicted_WT_Value, indicating that our signal to noise
ratio in this assay was poor. Visual inspection of the immunofluorescence signals from
imaging the protoarrays (Figure 14) shows high variability of the recurring control spots,
with weak signals especially in the upper left and lower right sections of the arrays
indicating possible uneven coverage of the array with the reaction mixture.
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Figure 14. Raw immunofluorescent images of ProtoArrays treated with HUNK.
Each circle is a protein spotted on the ProtoArray and imaged via immunofluorescent
detection of thiophosphate ester. Single experiment.
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Figure 15. Chart showing spot vs. spot signal for ProtoArrays treated with either
WT or K91M HUNK. Candidate substrates were defined as having WT signal four
times or more greater than that predicted from the K91M values. 26 paired spots had WT
signal four times or more less than that predicted from the K91M values. Note that
CAMKK2/CAMKKβ and CHEK2/CHK2 are alternate names for the same two proteins.
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Gene
Symbol
CAMKK2
BAZ2B
PHF23
SRPK3
CHEK2
PRPF38A
SMN2
NKAP
HIRIP3
C19orf43
MAP3K13
ASAP2
SSRP1
PRKCA
RTF1
POLB
MAP4K5
MAPKAPK5
PLK1

Description

Avg WT
Signal

Calcium/calmodulin-dependent protein kinase kinase 2
bromodomain adjacent to zinc finger domain, 2B
PHD finger protein 23
SFRS protein kinase 3
CHK2 checkpoint homolog (S. pombe)
PRP38 pre-mRNA processing factor 38 (yeast) domain containing A
survival of motor neuron 2, centromeric
NF-kappa-B-activating protein
HIRA interacting protein 3
chromosome 19 open reading frame 43
mitogen-activated protein kinase kinase kinase 13
Development and differentiation-enhancing factor 2
structure specific recognition protein 1
protein kinase C, alpha
Rtf1, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae)
polymerase (DNA directed), beta
Mitogen-activated protein kinase kinase kinase kinase 5
mitogen-activated protein kinase-activated protein kinase 5
polo-like kinase 1 (Drosophila)

2242
3884
1468
2224
2052
314
335
120
1237
239
56
98
480
1436
231
161
1820
191
689

Avg K91M
Signal
2
87
177
279
265
37
42
9
232
38
1
12
104
345
47
30
501
44
189

WT Signal
Actual WT
Predicted
Signal /
from K91M Predicted WT
Signal
Signal
10
225
81
48
156
9
242
9
230
9
40
8
44
8
16
7
203
6
41
6
10
6
19
5
95
5
297
5
48
5
34
5
428
4
45
4
166
4

Table 3. Ranked list of candidate substrates of HUNK. Confirmed substrates
highlighted in gray.

HUNK phosphorylates CHK2 and CAMKKβ and this activity is increased by
LKB1.
Two candidates were tested for substrate verification. CAMKKβ was chosen
because it was the strongest candidate and CHK2 was chosen because work performed in
our lab by Jason Jung indicated a role for HUNK in the DNA damage response. In both
cases, plasmids encoding FLAG-tagged, kinase dead variants were generated so as to
avoid signal from autophosphorylation. Proteins were expressed by transient transfection
in HEK-293T cells. CHK2-K249R protein lysate was found to inhibit HUNK activity
(data not shown), so the protein was subjected to a rapid purification and buffer exchange
over anti-FLAG antibody conjugated magnetic beads (SIGMA-ALDRICH) and
centrifugal concentrator (Millipore).
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Proteins were batch immunoprecipitated such that a portion of the beads could be
used to assess protein loading via a non-radioactive IP kinase assay and part used for
radioactive IP kinase assays with and without the addition of purified recombinant
LKB1/MO25α/STRADα (SIGMA-ALDRICH).
Incubation with WT but not K91M HUNK resulted in a significant increase in
phosphate deposited upon CHK2 and CAMKKβ, indicating that HUNK phosphorylates
these proteins in vitro (Figure 15). The phosphate deposited on HUNK, CHK2, and
CAMKKβ each increased when LKB1 heterotrimer was added to reactions with WT
HUNK, indicating that the increase in HUNK activity induced by LKB1 as measured by
autophosphorylation (Chapter 2) also results in increased phosphorylation of HUNK
substrates.
HUNK-WT basal activity was reduced by co-IP with CHK2-K249R as compared
to co-IP with CAMKKβ-K194A, which may indicate that CHK2-K249R associates with
HUNK in a manner that either impairs kinase activity or reduces access to HUNK
autophosphorylation sites. The increase in substrate phosphorylation induced by LKB1
was greater for HUNK phosphorylation of CHK2-K249R than for CAMKKβ-K194A,
though that may be due HUNK phosphorylation of CAMKKβ-K194A being nearly
saturated in this experiment while HUNK phosphorylation of CHK2-K249R was not.
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Figure 16. HUNK phosphorylates CHK2 and CAMKKβ and this activity is
increased by LKB1. Immunoprecipitation kinase assay using [γ-32P]-ATP and antiFLAG antibody-conjugated magnetic beads. Proteins were expressed by transient
transfection of HEK-293T cells. (A) Immunoblots from batch IP showing protein
loading on IP kinase assay. (B) Three autoradiographs taken at different exposures to the
gels from the IP kinase assay. (C) Quantification of phosphate deposited on CHK2K249R or CAMKKβ-K194A. Data are representative of more than three experiments,
each performed without replicate reactions.
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HUNK is required for efficient activation of ATM and CHK2 in response to DNA
damage.
To test whether HUNK phosphorylation of CHK2 may be physiologically
significant, we evaluated activation of the ATM/CHK2 pathway in cells after DNA
damage. LS174T human colon carcinoma cells were stably infected with hairpins against
either GFP as a negative control or against HUNK. NAF mouse MMTV-HER2/neu
tumor cells were stably infected with hairpins against either a non-targeting control or
against HUNK. Cells were then treated with the DNA alkylating (damaging) agent
adriamycin (doxorubicin) at 4 uM for 0, 30, 60, or 120 minutes and cells were lysed for
immunoblotting.
LS174T cells with HUNK knockdown show impaired activation of both ATM
and CHK2 (Figure 17). NAF cells with HUNK knockdown show impaired activation of
ATM. In both cell lines, HUNK is required to maintain total ATM protein levels after
DNA damage, as the knockdown cell lines show rapid degradation of ATM in inverse
proportion to the level of HUNK protein. CHK2 activation of Cdc25C is impaired in
LS174T cells with HUNK knockdown, further supporting the interpretation that HUNK
is required for ATM/CHK2 pathway activation. HER2 protein stability showed the same
relationship to HUNK as did ATM, i.e. reduced protein levels after DNA damage in
HUNK deficient cells.
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Figure 17. HUNK may be required for efficient activation of ATM and CHK2 in
response to DNA damage. LS174T or NAF cells with stable expression of either
negative control or anti-HUNK hairpins were treated with 4 uM adriamycin
(doxorubicin) for the indicated times. HeLa cells +/- UV treatment used as controls.
Single experiment.
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HUNK is does not affect kinase activity of CAMKKβ in vitro.
To test whether HUNK phosphorylation of CAMKKβ may be physiologically
relevant, we evaluated the effect of HUNK phosphorylation on CAMKKβ activity as
measured by phosphorylation of CaMKI. We generated FLAG-HUNK and FLAGCAMKKβ proteins via transient transfection of HEK-293T cells. Purified GST-CaMKI
was purchased from Abcam.
Because GST-CaMKI and FLAG-CAMKKβ migrate at the same electrophoretic
mobility, we removed the supernatant containing GST-CaMKI from the beads binding
FLAG-HUNK and FLAG-CAMKKβ after the kinase reaction. The beads were washed
and bead and supernatant material were run separately. We included CaMKI alone as a
control reaction and confirmed that there was no unprimed autophosphorylation by
CaMKI in this reaction. We also included +/- calcium/Calmodulin (gift of Kyle
Harpole).
As expected, calcium/Calmodulin increased kinase activity of CAMKKβ (Figure
18). There were no HUNK-dependent differences in CAMKKβ activity as measured by
phosphorylation of GST-CaMKI, suggesting that HUNK does not regulate kinase activity
or substrate interaction of CAMKKβ. It is still possible that HUNK regulates another
aspect of CAMKKβ such as protein stability or localization, but that possibility has yet to
be investigated.
It is interesting to note that CAMKKβ phosphorylated HUNK in this experiment,
with the difference between HUNK phosphorylation +/- CAMKKβ-WT was greater than
the difference between HUNK-WT and HUNK-K91M autophosphorylation. This
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suggests the possibility that CAMKKβ regulates HUNK which, if true, would also make
possible regulation of HUNK by cellular calcium flux.

HUNK and CAMKKβ are phosphorylated by HUNK, CAMKKβ, and LKB1 at
multiple sites.
To identify sites at which HUNK and CAMKKβ are phosphorylated we
performed IP kinase assays using [γ-18O4]-ATP (Cambridge Isotope Laboratories, >94%
18

O on γ-phosphate). FLAG-CAMKKβ was generated via transient transfection of HEK-

293T cells, FLAG-HA-mHUNK was generated via stable infection of NAF cells, and
LKB1/MO25/STRAD was purchased (SIGMA-ALDRICH). After the reaction was run,
beads were washed to remove LKB1 heterotrimer, beads were boiled in 1.5X RSB.
Samples were run on a PAGE gel, the gel was Coomassie stained, and bands were cut out
as indicated (Figure 19). Bands were sent to the Taplin Mass Spectrometry Facility at the
Harvard Medical School for analysis. Bands were subjected to independent tryptic and
chymotryptic digests, and peptides analyzed by tandem mass spectrometry. The
isotopically labeled ATP used in the kinase assay allowed us to distinguish between
phosphates deposited before and during the kinase assay.
The T-Loop had coverage in the chymotryptic digests and was not found to be
phosphorylated in this experiment. Numerous other phosphorylations were found in the
tryptic digests and assigned to the kinase(s) that could have deposited them (Table 4).
Phosphosites were distributed throughout the protein with no clear pattern of sequence
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preference beyond serine and threonine. It is probably that repeating this assay with
greater protein input would yield increased coverage and additional phosphosites.
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Figure 18. HUNK does not affect activity of CAMKKβ in vitro. HUNK and
CAMKKβ were expressed by transient transfection of HEK-293T cells and
immunoprecipitated onto anti-FLAG antibody conjugated magnetic beads for a kinase
assay using [γ-32P]-ATP. After kinase assay, supernatant with GST-CaMKI was
removed and run separately. (A) Immunoblot to determine protein loading after batch IP
for beads used in IP kinase assay. (B) Autoradiographs from IP kinase assay. Data are
representative of more than three experiments, each performed without replicate
reactions.
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Figure 19. MSMS identification of sites in HUNK and CAMKKβ phosphorylated
by HUNK, CAMKKβ, and LKB1. Immunoprecipitation kinase assay using [γ-18O4]ATP to isotopically label sites phosphorylated during the assay so they could be
identified via tandem mass spectrometry. (A) Coomassie stained gel with band cut sites
indicated. (B) Identity, quantity, and percent amino acid coverage of bands submitted for
MSMS phosphosite identification. Single experiment.
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HUNK
phosphorylated
by

HUNK
phosphorylated
at

HUNK

S65
S72
S299
S393
S398
S490
T507
S508
S510
S515
S517
S564
S588
S692
S700
S701
S703

HUNK HUNK
CAMKKβ CAMKKβ CAMKKβ
LKB1
S346
T352
S470
S516
S544
S546
S600
S605
S607
S608
S609
S617
S621
S690

T102
T105
T291
T403
S421
T424
T473
S497
S584

T287
S290
S344
T426
S463
S588
T618

.
LKB1

CAMKKβ
phosphorylated
by

S678

CAMKKβ
phosphorylated
at

HUNK

S27
S105
S113
S128
S198
S335
S341
S359
S496

HUNK HUNK
CAMKKβ CAMKKβ CAMKKβ
LKB1
S23
S90
S112
S115
S149
S153
T167
S346
T348
T351
T448
S481
T484
T490
S523
S526

S510
S512
T519

S44
S51
S111
T146
T363

.
LKB1
T463
S504

Table 4. MSMS identification of sites in HUNK and CAMKKβ phosphorylated by
HUNK, CAMKKβ, and LKB1.
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DISCUSSION
We have purified HUNK and used this material to search for substrates via kinase
assays on protein microarrays. The protein microarray kinase assay using ATPγS and
immunofluorescence enabled generation of a ranked list of candidate substrates of
HUNK kinase, two of which have been verified using immunoprecipitation kinase assays
(IPKAs) using [γ-32P]-ATP. We have also uncovered evidence that HUNK regulation of
the DNA damage response is physiologically relevant in at least two cell lines, with the
possibility that HUNK phosphorylation of CHK2 is involved.
The use of the IPKA to confirm 2 of the 19 candidate substrates of HUNK
supports the idea that other substrates can be found on that list. It is also possible that
repeats of the kinase assay on protein microarrays with greater amounts of protein or
more active protein would augment the list of candidate substrates of HUNK. It is
noteworthy that 3 of the 19 substrates of HUNK are found in the MAPK pathway
(MAP3K13, MAP4K5, MAPKAPK5).
HUNK phosphorylation of CHK2 led us to evaluate activation of ATM and
CHK2 after DNA damage, and we found HUNK dependent regulation of both proteins.
This suggests that ATM may be another HUNK substrate and this should be
experimentally evaluated. Furthermore, it is possible that HUNK regulates other proteins
involved in response to DNA damage, such as ATR/CHK1, and this too should be
addressed experimentally. The mechanism for such regulation is at present entirely
unknown. We do not know where HUNK phosphorylates CHK2 or what effect that
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phosphorylation may have, but it is possible that it could alter CHK2 stability,
localization, kinase activity, or protein:protein interaction.
ATM is known to stabilize HER2 protein levels by promoting the interaction
between HSP90 and HER2, promoting the tumorigenicity of HER2166. This supports the
finding that HUNK knockdown, which resulted in reduced ATM protein levels after
DNA damage, correlates with reduced HER2 protein. This also suggests one mechanism
by which HUNK promotes and is required for HER2/neu induced tumorigenesis: the
stabilization of ATM after DNA damage, resulting in prolonged HER2 signaling during
cellular DNA damage stress. HUNK is required for activation of nuclear Akt after DNA
damage (Jung et. al., submitted), suggesting another possible link with HSP90, which
binds to and regulates the activity of Akt167,168.
While HUNK did not alter kinase activity of CAMKKβ in vitro, we did not
address the effect of CAMKKβ phosphorylation of HUNK. It is possible that CAMKKβ
phosphorylates the T-Loop of HUNK as CAMKKβ does for AMPKα79, acting as another
upstream activating kinase. CAMKKβ acts as the dominant activator of AMPK in certain
tissues, resulting most notably in CAMKKβ-AMPK dependent regulation of appetite in
the hypothalamus169. Both CAMKKβ and HUNK show highest expression in the
brain12,170. If CAMKKβ were to regulate HUNK, it would provide HUNK with
sensitivity to calcium flux and extend the possibilities for HUNK-dependent phenotypes.
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CHAPTER 4: SUMMARY AND FUTURE DIRECTIONS
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SUMMARY

We have demonstrated that contrary to published predictions, LKB1 activates
HUNK kinase by phosphorylating a conserved threonine residue (T222) in its T-Loop.
Our experiments with in vitro translated protein indicate that this reaction requires no
factors other than HUNK and the LKB1/MO25/STRAD heterotrimer and that HUNK
likely has some intrinsic activity even in the absence of LKB1 activation. We also
described data indicating that while LKB1 can phosphorylate HUNK at residues outside
of the T-Loop, phosphorylation at these sites does not appear to influence LKB1
dependent control of the kinase activity of HUNK. Crucially, we showed that LKB1
controls HUNK activity in vivo as LKB1 overexpression activated HUNK, expression of
dominant negative LKB1-D194A reduced HUNK activity, and shRNA against LKB1
lowered HUNK activity.
Our data show that HUNK binds to LKB1 heterotrimers containing STRADβ but
not STRADα, raising important questions about the role of compartmentalization in the
regulation of both HUNK and LKB1.
We also purified HUNK and used that material in a kinase assay on a protein
microarray. We were able to generate a ranked list of candidate substrates of HUNK,
including the first two substrates identified, CAMKKβ and CHK2. Following up on the
identification of CHK2 as a substrate of HUNK, we’ve shown that HUNK is required in
some cell lines for efficient activation of the ATM/CHK2 pathway in response to DNA
damage, in part by regulating the stability of both ATM and HER2 after DNA damage.
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FUTURE DIRECTIONS – HUNK AND LKB1

Does STRAD isoform impact HUNK activation in vivo?
We found that WT HUNK binds to LKB1, MO25, and STRADβ but not
STRADα (Figure 9). This suggests the possibility that HUNK is activated preferentially
by complexes of LKB1 that contain STRADβ but not STRADα. We know that HUNK
can be activated in vitro by LKB1 complexes that contain STRADα because the purified
recombinant LKB1 heterotrimer we used in our IPKAs (immunoprecipitation kinase
assays) contained only STRADα. However, it is possible that in living cells, HUNK is
preferentially activated by complexes with STRADβ.
One method for evaluating this would be to knockdown, via either siRNA or
shRNA, each isoform of STRAD. If HUNK is preferentially activated by STRADβ, then
knockdown of the β but not the α isoform of STRAD should reduce the activity of
HUNK from those cells as evaluated by IP kinase assay.

How does HUNK bind to the LKB1 heterotrimer?
Questions remain regarding the mode of interaction between HUNK and the
LKB1 heterotrimer. Does HUNK bind directly to one or more members of
LKB1/MO25/STRAD? Our current data is most consistent with the idea that HUNK
binds directly to STRADβ. For the kinase assay in figure 16, HUNK was incubated with
purified recombinant LKB1/MO25α/STRADα for 30 minutes, after which the
supernatant with LKB1 heterotrimer was removed and the beads were washed. Equal
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amounts of GST-STRAD remained on the beads to which HUNK-WT, HUNK-K91M,
and Empty Vector control lysate were immunoprecipitated, suggesting that under those
conditions, LKB1/MO25α/STRADα did not bind to HUNK. However, a better way to
determine binding would be to design an experiment specifically to address the question.
Using in vitro translated protein, we can generate HA-tagged LKB1, MO25,
STRADα, STRADβ alone, then incubate with FLAG-HUNK bound to anti-FLAG
antibody conjugated beads. This would allow us to determine whether HUNK binds
directly to a single member of the LKB1 heterotrimer. To further understand how
HUNK binds to the LKB1 heterotrimer, we could repeat the co-immunoprecipitation
experiment as it was performed in figure 9 but using truncation mutants or short segments
of FLAG-HUNK instead of full-length protein. We have such expression vectors in lab.
With the region of binding identified, we can perform alanine scanning mutagenesis to
find point mutants that abrogate binding, which would represent possible disease states in
which HUNK activity would be reduced.

Is nuclear localization required for HUNK activation?
WT HUNK is both nuclear and cytoplasmic while K91M HUNK is excluded
from the nucleus159. WT HUNK binds exclusively to LKB1 heterotrimers containing
STRADβ (Figure 9), which are predominantly nuclear (Figure 1B)51, while K91M
HUNK only very weakly binds LKB1 heterotrimer components. If binding to the LKB1
heterotrimer increases the efficiency of HUNK activation, then nuclear localization
would be required for full activation of HUNK by LKB1. We can test the requirement
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for nuclear localization in HUNK activation by creating a fusion of HUNK with
ubiquitin, which forces HUNK cytoplasmic localization (unpublished observation), and
comparing the activity of cytoplasmic HUNK-ubiquitin to that of WT HUNK. We can
also test the converse, i.e. whether forcing nuclear localization of K91M HUNK
promotes interaction with STRADβ containing LKB1 heterotrimers or increases LKB1
phosphorylation of T222 by fusing K91M HUNK with the 3XSV40 large tag NLS
(nuclear localization sequence).

Does HUNK alter the nuclear/cytoplasmic distribution of LKB1?
The orphan nuclear receptor Nur77 binds to nuclear LKB1, increasing its
nuclear/cytoplasmic ratio and reducing AMPK activation. WT HUNK binds to LKB1
complexes containing the primarily nuclear STRADβ. This suggests the possibility that
HUNK binding stabilizes LKB1 in the nucleus, shifting its nuclear/cytoplasmic ratio and
reducing AMPK activation. LKB1 nuclear/cytoplasmic ratio can most directly be
evaluated by cellular fractionation, wherein cytoplasmic proteins and nuclear proteins can
be immunoblotted separately. If modulation of HUNK levels via either overexpression
or knockdown leads to an altered nuclear/cytoplasmic ratio of LKB1 in a given cell line,
then it is possible that AMPK activation will be altered as well. AMPK activation can be
evaluated by treating the cells with known activators such as the AMP mimetic AICAR
(5‑aminoimidazole‑4-carboxamide‑1‑β‑d-ribofuranoside) or the biguanide phenformin
and blotting for activated AMPK and at least one of its substrates such as ACC (Acetyl
Coenzyme A Carboxylase)171.
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FUTURE DIRECTIONS – SEARCHING FOR AND VALIDATING HUNK
SUBSTRATES

Does CAMKKβ regulate HUNK?
Our data show much greater phosphate deposited on HUNK in reactions with WT
CAMKKβ as compared to K194A (kinase dead) CAMKKβ, indicating that CAMKKβ
phosphorylates HUNK. CAMKKβ phosphorylates AMPKα at the same conserved
threonine phosphorylated by LKB1, activating AMPK and providing sensitivity to
calcium flux in certain tissues169,172,173. It may be that CAMKKβ phosphorylates the
conserved threonine in HUNK (T222) to activate HUNK in the same manner as LKB1.
We plan to test this using a kinase assay similar to that shown in figure 18. We will co-IP
FLAG-HUNK, FLAG-CAMKKβ, and a fragment of FLAG-CHK2 (this fragment
migrates at different apparent molecular weight than other components of this reaction)
onto anti-FLAG antibody conjugated magnetic beads and then perform a kinase assay
using [γ-32P]-ATP. If CAMKKβ phosphorylation of HUNK increases its kinase activity,
there should be greater phosphate deposited on the FLAG-CHK2 fragment when it is coimmunoprecipitated with both WT HUNK and WT CAMKKβ. If CAMKKβ
phosphorylates and activates HUNK, it will provide a means to link HUNK activity to
calcium flux.
If CAMKKβ phosphorylates HUNK at other sites, it may or may not be
physiologically significant, as for instance the non-T-Loop sites at which LKB1
phosphorlyates HUNK have no demonstrated biological role. It is possible that
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CAMKKβ phosphorylation of HUNK at non-T-Loop sites could regulate other aspects of
HUNK biology such as protein stability, localization, or interaction with other proteins.
Each of these could be assessed in cells by both overexpression and knockdown of
CAMKKβ followed by an experiment in the modified cells. Altered HUNK protein
stability can be determined by using cycloheximide to block translation of new HUNK
and evaluating the quantity of HUNK present in cellular lysate over time. As HUNK is
rapidly degraded in response to a wide variety of cellular stresses (data not shown), it
would be important to include at least one of these stresses (ER stress induced by
thapsigargin) in this experiment to find out whether CAMKKβ alters HUNK stability
after stress in the same way that HUNK alters ATM and HER2 stability after DNA
damage. Altered localization could be detected by either cell fractionation or
immunofluorescence. Altered protein binding of HUNK would be detected by coimmunoprecipitation assays and 14-3-3 and USP9X should be evaluated as they are
binding partners of ARKs whose interaction is known to be regulated by
phosphoryation88,90.

Where does HUNK phosphorylate CHK2 and CAMKKβ?
We plan to perform additional kinase assays to localize sites where HUNK
phosphorylates CHK2 and CAMKKβ, now using soluble protein and [γ-18O4]-ATP. We
anticipate improved coverage and preservation of phosphorylation for two reasons:
higher input protein amounts and avoiding the need to elute protein from beads used in
the IP kinase assays, achieved by boiling in our former workflow174. We have developed
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a system for rapid expression and purification of large quantities of protein in sf9 insect
cells using the pFastBac vector as a starting point. WT HUNK protein produced in this
fashion is kinase active and that activity can be raised by LKB1 (data not shown).
Producing substrate proteins in this fashion, or in bacteria, will rapidly produce
significantly more protein than that obtained via transient expression in HEK-293T
cells175. The use of [γ-18O4]-ATP allows us to once again identify phosphates deposited
during our kinase reaction. We plan to generate a ranked list of candidate sites and
confirm by evaluating phosphorylation of mutants in which the candidate site has been
mutated to alanine.
Should the above method for identification of phosphosites fail, we plan to move
to an approach published in 2010. This method uses ATPγS to thiophosphorylate
substrates, the substrates are digested, and thiophosphorylated peptides are covalently
captured onto disulfide resin and then released using base hydrolysis (NaOH) before
being identified by mass spectrometry176.

What other candidate HUNK substrates can be verified?
Table 3 lists 17 untested candidate substrates of HUNK. Knowledge of kinase
substrates is vital to understanding kinase biology, and with 2 substrates on the list
already confirmed, there is no better place to continue searching for HUNK substrates
than on this list.
By score, BAZ2B (bromodomain adjacent to zinc finger domain, 2B) is the most
likely candidate on the list. It is an understudied member of the bromodomain family of
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proteins which are involved in regulation of transcription through control of chromatin
remodeling. The second strongest untested candidate by score is another understudied
protein involved in chromatin remodeling, PHF23 (plant homeodomain finger protein
23). Also on the candidate list is RTF1, another chromatin remodeling protein177. A
connection can be made between these three proteins as HUNK expression is higher in
poorly differentiated tumors of the colon and ovaries6, poorly differentiated tumor cells
very often have an expression profile with significant overlap with embryonic stem
cells178, and stem cell self-renewal is controlled in party by chromatin remodeling
proteins179. It is possible that HUNK could promote an expression profile similar to stem
cells by control of these two chromatin remodeling factors.
There are also three proteins from the MAPK pathway (MAP3K13, MAP4K5,
MAPKAPK5), two proteins required for DNA damage repair (CHK2, POLB), and a total
of eight kinases. With two proteins confirmed by IP kinase assay, we plan to continue
evaluating these candidates by generating the protein in house using transient transfection
of HEK-293T cells and subjecting them to the IPKA. Each of the kinases on the list will
first need to be mutationally inactivated to reduce background signal from
autophosphorylation.
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FUTURE DIRECTIONS – HUNK, ATM/CHK2, AND THE DNA DAMAGE
RESPONSE

Does HUNK regulate ATM and CHK2?
We initially identified CHK2 as a candidate substrate of HUNK using a kinase
assay on a protein microarray (ProtoArray). We subsequently confirmed HUNK
phosphorylation of CHK2 in an immunoprecipitation kinase assay using kinase dead
CHK2-K249R. As an initial investigation into whether HUNK phosphorylation of CHK2
has physiological relevance, we asked whether DNA damage induced activation of
ATM/CHK2 was altered in cells expressing shRNA against HUNK. We stably infected
both LS174T human colon carcinoma and NAF murine MMTV-neu each with control
non-targeting hairpin and two different hairpins against HUNK. We treated these cells
with the DNA alkylating agent Adriamycin and immunoblotted to evaluate activation of
the ATM/CHK2 pathway. In the HUNK deficient cell lines treated with Adriamycin, we
saw impaired activation of both ATM and CHK2, as well as reduced stability of both
ATM and HER2, suggesting that HUNK is required both for efficient activation of
ATM/CHK2 and for maintenance of ATM and HER2 protein levels in response to DNA
damage.
These data lead to two broad questions. First, we plan to assay other cell lines,
tissues, and patient samples to ask in what contexts HUNK regulates DNA damage
induced ATM/CHK2 activation and protein stability. The set of cells with which we plan
to begin this investigation is a subset of the ATCC (American Type Culture Collection)
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Breast Cancer Cell Panel, from which we have generated several cell lines with HUNK
levels altered either by shRNA knockdown or overexpression. We may find that HUNK
regulates ATM/CHK2 only in certain breast cancer subtypes or in cell lines driven by
particular oncogenes, knowledge important for the potential therapeutic application of
this discovery.
Second, how does HUNK control ATM/CHK2? As discussed in chapter 3, the
answer begins with learning where HUNK phosphorylates CHK2, which may suggest the
mode of regulation as many phosphosites in CHK2 have known effects180. We also must
investigate whether HUNK phosphorylates ATM by generating a kinase dead variant and
using it as a substrate in a kinase assay with HUNK WT and K91M. The data we already
have suggests postulation of a mechanism by which HUNK could regulate ATM, HER2,
and Akt.
ATM stabilizes HER2 protein levels by promoting the interaction between HSP90
and HER2, prolonging HER2 signaling and promoting the tumorigenicity of HER2166. If
HUNK plays a role in the stabilization of HER2 by ATM and HSP90, this would provide
a mechanism to explain how HUNK is required for HER2/neu induced mammary
tumorigenesis7. HSP90 is also a possible link between HUNK and Akt. HUNK is
required for activation of nuclear Akt after DNA damage (Jung et. al., submitted), and
Akt, like HER2, binds to and is regulated by HSP90167,168. These three phenotypes could
each be explained by HUNK regulation of the interaction of HSP90 with its client
proteins, and other phenotypes would be predicted by this finding.
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We plan to analyze HUNK regulation of DNA damage induced activation of
ATM/CHK2 by with immunoblots for pathway activation after DNA damage induced by
both Adriamycin and γ-IR. We also plan to examine the efficiency of homologous
recombination in HUNK deficient and WT cells using a GFP reporter based assay in
which GFP expression follows HR-directed repair of a double strand break induced by
transient transfection of the I-SceI endonuclease181.

Does HUNK regulate the DNA Damage Response?
We have preliminary data indicating a requirement for HUNK in one DNA repair
pathway, but almost no data on whether HUNK is involved in other DNA repair
pathways. One hint that HUNK might be comes from the list of candidate substrates
(Table 3), which contains POLB (DNA Polymerase Beta), a DNA polymerase involved
in base excision and repair. However, there are a number of experiments that can
illuminate HUNK’s role in the DNA damage response.
Does HUNK localization alter after DNA damage? After DNA damage, many
DNA damage response proteins exhibit punctate nuclear staining, colocalize with γH2AX, and co-immunoprecipitate with DDR proteins182. If HUNK does so, this is
evidence of involvement in the DNA damage response. We plan to evaluate these factors
in HEK-293T cells and in U2OS cells, two cell lines commonly used in experiments on
the DDR. We plan to modify their HUNK expression, in U2OS cells with shRNA
against HUNK or non-targeting negative control and HEK-293T cells with transient
overexpression of either WT or K91M HUNK as well as empty vector control. We’ll
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treat cells with Adriamcyin or γ-IR before evaluating HUNK localization and colocalization by immunofluorescence. We also plan to evaluate HUNK binding by
immunoprecipitation assays before and after DNA damage, with particular focus on
whether HUNK binds to ATM, CHK2, or components of the MRN complex, a primary
sensor of DNA double strand breaks183.
We also plan to confirm HUNK regulation of the DDR by examining the kinetics
of DNA repair in cells. Our first experiments will again use U2OS and HEK-293T with
modified HUNK expression. We plan to use two common assays for the measurement of
DNA repair kinetics. First is the comet tail assay, also known as single cell gel
electrophoresis, which can give a single broad measurement that integrates multiple
forms of DNA damage for each cell in the assay184,185. Second is the counting of γH2AX foci via immunofluorescence. γ-H2AX foci form in response to DNA double
strand breaks and disappear as DNA is repaired186,187. With these two measurements, we
will gain insight into the requirement of HUNK for efficient repair of DNA damage.
Several independent labs have proven that LKB1 regulates repair of multiple forms of
DNA damage induced by γ-IR136, UV illumination141, and H2O2142. Our prediction is
that HUNK mediates at least a fraction of the LKB1 dependent repair of DNA damage
and this will lead to a measurable defect in DNA damage repair in HUNK deficient cells
and may accelerate DNA repair kinetics in cells overexpressing HUNK. It will also be
important to assess whether HUNK regulates the activation of the ATR/CHK1 DNA
repair pathway, the second major pathway for cellular repair of DNA double strand
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breaks. This can be evaluated by treating these cells with DNA damage agents and
blotting for the activated forms of ATR and CHK1.
To highlight the physiological relevance of HUNK, we will measure cell cycle
arrest and survival after DNA damage in cells deficient for HUNK. Cells that fail to
repair DNA damage eventually undergo cell cycle arrest and/or apoptosis188. A
consequence of the prediction that HUNK is required for efficient repair of DNA damage
is that cells deficient for HUNK would be more likely to undergo DNA damage induced
cell cycle arrest or apoptosis. We can measure these two parameters by well established
methods. Cell cycle arrest due to DNA damage leads to an increase in cells with 4N
DNA content as they arrest at the G2/M checkpoint. This increase in DNA per cell can
be quantified by flow cytometry after staining cells with propidium iodide. The
propidium iodide assessment of cell cycle can be multiplexed with staining with
fluorescently labeled annexin V to detect apoptosis, allowing a single experiment to
quantify both cell cycle arrest and apoptosis at the level of the single cell189.
If HUNK deficient cells are deficient in DNA damage repair, we predict they will
be more sensitive to therapies that induce DNA damage, in particular PARP (poly (ADPribose) polymerase) inhibitors136. This can be measured in several ways, and we plan to
assess this sensitivity treating cells with the PARP inhibitor 6(5H)-phenanthridinone
(PHEN) before assessing cell viability using trypan blue exclusion and our automated cell
counter, the Vi-Cell (Beckman-Coulter).
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FUTURE DIRECTIONS – HUNK AND TGFβ

Does HUNK regulate TGF-β signaling?
As discussed in chapter 2, there are data to suggest that LKB1 regulates TGF-β
signaling via effectors that have yet to be determined. The gastrointestinal tracts of mice
deficient for stromal LKB1 form polyps indistinguishable from PJS polyps156. While
LKB1-/- stromal cells exhibit unperturbed mTOR, AMPK, SRF, RhoA, and FAK
signaling157, they produce less TGF-β, a defect which results in increased proliferation of
epithelial cells in both murine and human PJS tissues158. As both HUNK and TGF-β
have been shown to down-regulate MYC expression and lead to inhibition of CDKs8,154,
it is intriguing to speculate that HUNK may play a role in mediating the relationship
between LKB1 and TGF-β signaling.
As an initial investigation, we could treat cells with altered HUNK expression
with TGF-β1 and examine pathway activation via immunoblot for phospho-SMAD3. As
Li et. al. have shown, cells engineered to alter expression levels of LKB1 show an inverse
correlation between LKB1 expression levels and TGF-β1 induced activation of
SMAD3190. As a control for cells with altered HUNK expression, cells with altered
LKB1 expression should be used in the experiment as this will allow us to determine
what fraction of the phenotypic effect is mediated by HUNK. Should this work reveal
HUNK dependent regulation of TGF-β, further investigation will follow.
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OVERALL CONCLUSIONS
Previous publications from our lab have demonstrated that HUNK plays a role in
the development and progression of cancer in multiple contexts. HUNK is required for
tumorigenesis in murine models of breast cancer driven by HER2/neu overexpression or
by PTEN deletion7,8. HUNK is also required for metastasis of tumors driven by c-MYC6.
While the precise molecular mechanisms controlling HUNK-dependent phenotypes are
unknown, several mechanistic details are known. HUNK suppresses apoptosis in mouse
models of cancer driven by HER2/neu overexpression or PTEN deletion7,8, in the former
by negative regulation of p27kip1 expression and nuclear localization and in the latter by
negative regulation of c-Myc expression. HUNK also promotes survival in the involuting
mammary gland.
To better understand HUNK dependent phenotypes, we investigated the activation
of HUNK. We proved that LKB1 activates HUNK by phosphorylating a conserved
threonine (T222), and demonstrated that this is sufficient and required for HUNK
activation in vitro and in vivo. This finding indicates that HUNK is an effector kinase for
LKB1, suggesting that HUNK may control LKB1 dependent regulation of DNA damage
repair or TGF-β signaling, both phenotypes for which mechanisms are incompletely
understood.
To gain insight into the molecular mechanisms that underlie HUNK dependent
phenotypes, we searched for substrates of HUNK using a kinase assay on a protein
microarray. We highlighted 19 candidate substrates of HUNK and the first two
substrates from that list to be tested, CHK2 and CAMKKβ, have been confirmed in
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immunoprecipitation kinase assays. We have preliminary data to suggest that HUNK
phosphorylation of CHK2 is physiologically significant as cells in which HUNK has been
silenced by shRNA are deficient for activation of ATM/CHK2 in response to DNA
damage. We plan to test additional substrates of HUNK from our candidate list, which
includes three candidates linked to regulation of stem cell differentiation through
structural regulation of chromatin and three candidates from the MAPK pathway.
In summary, we propose that HUNK is an LKB1 effector kinase. The activation
of HUNK by LKB1 is likely to be required for HUNK mediated anti-apoptotic and promigratory effects in tumors driven by overexpression of HER2/neu and c-Myc and by
deletion of PTEN. Further, it is possible that HUNK controls or contributes to multiple
LKB1-dependent phenotypes. In particular, the current understanding of LKB1
dependent regulation of the DNA damage response is incomplete. Given our preliminary
data that HUNK phosphorylates CHK2 and, in some contexts, is required for activation
of the ATM/CHK2 pathway, it is likely that inhibition of HUNK will prove a useful
therapeutic strategy that can synergize with existing therapies designed to promote DNA
damage such as PARP inhibitors and standard platinum based chemotherapeutic agents.
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